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3Abstract
Background and aims. Type 2 diabetic patients have a three- to four-fold risk of 
cardiovascular disease. A cluster of cardiovascular risk factors has been identifi ed 
(high blood pressure, high triglycerides, low HDL cholesterol, obesity, impaired 
glucose metabolism), which together constitutes the metabolic syndrome. 
The metabolic syndrome affects up to 80 per cent of type 2 diabetic patients. 
Infl ammation, endothelial activation, and the growth factor system derangement 
are all novel cardiovascular risk factors. The present studies were undertaken to 
explore the roles of the insulin-like growth factor system, low-grade infl ammation, 
and endothelial dysfunction in relation to incipient atherosclerosis, traditional 
cardiovascular risk markers, and the metabolic syndrome especially in type 2 
diabetes.
Subjects and methods. Two hundred and thirty-nine type 2 diabetic subjects aged 
50 to 75 were recruited from participants of the FIELD (Fenofi brate Intervention 
and Event Lowering in Diabetes) study at the Helsinki centre. Additionally, 
a healthy control group (N = 93) was also recruited. The examinations were 
performed during the placebo run-in phase of the FIELD study for the diabetic 
patients. An extensive list of lipids and lipoproteins, infl ammatory markers, 
endothelial markers, and IGF system variables was determined. Albumin 
excretion rate was measured. Carotid arteries were scanned for the determination 
of intima-media thickness (IMT) as a surrogate marker of atherosclerosis. Pulse-
wave analysis (PWA) was performed to determine central arterial augmentation 
and augmentation index  (AIx) to measure arterial stiffness. In a subset (N = 99), 
carotid scans were reread to determine the severity of local soft and mineralised 
vessel wall thickening.
Results. Compared with the control group, IMT was thicker in diabetic 
subjects. Blood pressure, age, gender, the duration of diabetes, dyslipidaemia, 
and obesity were positively related to IMT in diabetic subjects.  In contrast, 
insulin-like growth factor binding protein-1 (IGFBP-1) was inversely related to 
IMT in diabetic subjects. In healthy subjects, the determinants of IMT were age, 
infl ammation, endothelial activation, LDL cholesterol, and insulin resistance, 
but not blood pressure. Among diabetic subjects IGFBP-1 was a marker of 
insulin sensitivity and inversely related to the severity of the metabolic syndrome. 
Low-grade infl ammation and endothelial dysfunction were enhanced in type 
2 diabetes. Among diabetic patients, the severity of the metabolic syndrome 
correlated strongly with the levels of markers for infl ammation and endothelial 
activation. The concentrations of these markers were not related to clinical 
cardiovascular disease among diabetic patients. Central pressure augmentation, 
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4AIx, and IMT correlated with each other and with the severity of local vessel 
wall thickening. Diabetic women had higher augmentation and AIx values than 
men after controlling for confounders. Determinants of AIx in diabetic subjects 
were blood pressure, albuminuria, and IMT, and to a lesser extent, obesity and 
endothelial dysfunction.
Conclusions. 1) IGFBP-1 and AIx could potentially be useful in detecting 
subjects with cardiovascular risk among diabetic patients. 2) Low IGFPB-1 is a 
good marker of insulin resistance and the metabolic syndrome. 3) Diabetes has a 
more detrimental effect on arterial compliance in women than in men. 4) Low-
grade infl ammation and endothelial dysfunction are enhanced in diabetes, but 
do not differ between diabetic patients with or without cardiovascular disease in 
a cross-sectional setting.
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1. Introduction
The number of people with diabetes has risen dramatically during the last decades. 
The prevalence of diabetes in adults (>20 years) worldwide was estimated to be 
135 million in 1995 (King et al. 1998). If the epidemic of diabetes continues as 
predicted, the estimated global prevalence in adults will rise to 366 million by 
2030 (Wild et al. 2004). 
People with type 2 diabetes have a three to four -fold increased risk for 
cardiovascular disorders such as coronary heart disease (CHD), myocardial 
infarction (MI), transient ischaemic attack (TIA), stroke, peripheral vascular 
disease, and amputations (Howard et al. 2002).  Approximately 75% of deaths 
among type 2 diabetic patients are accounted for by cardiovascular disease 
(Laakso and Lehto. 1998). Thus the epidemic of diabetes will be followed by a 
similar wave of cardiovascular disease (CVD) worldwide.
Age, family history, diabetes, hypertension, smoking, high total and LDL 
cholesterol, low HDL cholesterol, and obesity are established risk factors for 
atherosclerosis in the general population (Faxon et al. 2004, Fruchart et al. 
2004). More recently, small dense LDL, elevated triglycerides, and homocystein, 
among others, have become established as cardiovascular risk factors (Fruchart 
et al. 2004).  Overall, the effects of multiple traditional CVD risk factors are 
additive (Neaton et al 1992). 
Recently, several novel cardiovascular risk factors have been identifi ed. 
Infl ammation is an important factor at all stages of atherosclerosis, and has 
been the topic of extensive research (Hackam 2003). Increasing evidence on the 
essential role of endothelial dysfunction in atherothrombotic vascular disease is 
accumulating (Smith et al. 2004). 
In diabetic individuals, the CVD risk caused by any individual risk factor or 
any combination of risk factors rises more steeply than in non-diabetic subjects 
(Stamler et al. 1993). At any given number of risk factors, diabetic individuals 
have an approximately 3-fold CV risk. This indicates a specifi c, diabetes-related 
risk. Toxic effects of hyperglycaemia, derangement of coagulation and fi brinolysis, 
platelet hyperaggregability, oxidative stress, and autonomic neuropathy play a 
role in the excess CV morbidity (Hurst 2003). Data is also accumulating on 
detrimental postprandial metabolism with hyperglycaemia and elevation of 
atherogenic lipoproteins in type 2 diabetic patients (Taskinen 2003, Heine et al. 
2004, Krauss 2004).  
1. INTRODUCTION
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The metabolic syndrome accompanies type 2 diabetes in four out of fi ve type 2 
diabetic patients (Isomaa et al. 2001). The underlying metabolic disorder and 
central feature of the metabolic syndrome is insulin resistance. Insulin resistance 
is associated with an enhanced infl ammatory state and vascular endothelial 
dysfunction, a tendency to thrombosis, and impaired thrombolysis (Pickup 
2004). Therefore, several of the newly identifi ed cardiovascular risk factors are 
actually features of the metabolic syndrome. 
The metabolic syndrome precedes and predicts both CVD and incipient type 2 
diabetes (Betteridge 2004). The metabolic syndrome has been reported to be an 
independent risk factor of cardiovascular disease (CVD), irrespective of the level 
of glucose tolerance (Isomaa et al. 2001). The concentrations of infl ammatory 
markers identifi ed as cardiovascular risk factors are already elevated in insulin-
resistant individuals before the diagnosis of diabetes (Festa et al. 2003). 
Cardiovascular disease and diabetes seem to develop simultaneously. Diabetes 
often remains subclinical until presentation of an acute clinical cardiovascular 
event (Norhammar et al. 2002).
Finally, hormonal factors such as an overactive hypothalamic-pituitary-adrenal 
axis, deranged insulin-like growth factor system, and altered hormonal secretory 
activity of the adipose tissue seem to be components of insulin resistance 
syndrome and risk factors for atherosclerosis (Pickup 2004).  
The complex mechanisms underlying the relationship between atherosclerosis, 
type 2 diabetes and the metabolic syndrome are not well understood yet. One 
key question that remains unanswered is whether insulin resistance precedes 
infl ammation or vice versa.
The present study has explored these relationships in a cross-sectional setting in 
type 2 diabetic patients participating in the prospective part of the Fenofi brate 
Intervention and Event Lowering in Diabetes (FIELD) study.   
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2. Review Of The Literature
2.1. Defi nition, pathogenesis, and epidemiology 
of type 2 diabetes
According to the criteria of the World Health Organisation (WHO 1999), a 
fasting plasma glucose concentration of 7.0 mmol/l and above, on two occasions, 
indicates diabetes. The diagnostic criterion for diabetes in the 75g oral glucose 
tolerance test (OGTT) is a 2-hour post-challenge value of 11.1 mmol/l or 
above.
According to the WHO defi nition, type 2 diabetes “is the most common form of 
diabetes and is characterized by disorders of insulin action and insulin secretion, 
either of which may be the predominant feature. Both are usually present at the time 
that this form of diabetes is clinically manifest. By defi nition, the specifi c reasons for 
the development of these abnormalities are not yet known”.  Disturbance in both 
insulin secretion and insulin action, i.e. insulin resistance, vary greatly among 
type 2 diabetic patients (WHO 1999).  The relative importance of insulin 
secretion defi ciency and insulin resistance has been debated, but current evidence 
indicates that both are present early in the natural course of the development of 
type 2 diabetes (Kahn 2003).  Over time, a progressive deterioration of beta-cell 
function leads to a decline in glucose tolerance (Matthews et al. 1998, Weyer et 
al. 1999).
The individual’s risk to type 2 diabetes is determined by both genetic and 
environmental factors. Unequivocal evidence for the heritability of type 2 
diabetes based on twin studies and also studies on fi rst-degree relatives of type 2 
diabetic subjects exists  (McIntyre and Walker 2002). Susceptibility genes have 
been sought by candidate gene, affected sib pair analysis, and genome wide scan 
approaches. There have been studies conducted on different high risk populations 
including Pima Indians and inhabitants of Nauru island, as well as in isolated 
cohorts, e.g. the Amish, etc. (Van Tilburg et al. 2001). Current data suggest a 
complex genetic background. 
According to the “thrifty phenotype hypothesis,” originally introduced by Barker 
and colleagues (Hales et al. 1991) and reinforced by several research groups 
(reviewed by Barker 2004), poor intrauterine nutrition renders individuals 
predisposed to type 2 diabetes in adult life. The central element of the hypothesis 
is that poor foetal and infant nutrition leads to disturbed programming of 
glucose-insulin metabolism (Hales and Barker 2001). 
2. REVIEW OF THE LITERATURE
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Lifestyle infl uences whether a genetically and in utero predisposed individual 
develops type 2 diabetes. Such lifestyle factors include dietary intake and physical 
activity, the resulting weight, and the amount and distribution of adipose tissue, 
especially accumulation of central fat (Wing et al. 2001). There is an interaction 
between genetic and environmental factors. Specifi c genes that partly determine 
the protective effect of lifestyle changes on the risk of diabetes have been identifi ed 
(Todorova et al. 2004, Shuldiner et al. 2004).
The incidence and prevalence of type 2 diabetes is exploding in most populations, 
the rate of increase being most marked in the Third World (Diamond 2003). 
The number of diabetic patients worldwide was estimated to be 135 million 
in 1995 (King et al. 1998), and 171 million in 2000 (Wild et al. 2004), but is 
predicted to rise to 366 million by 2030 in people over 20 years of age (Wild et 
al. 2004).  The main reasons for the diabetes epidemic are the growing number 
of people over 65 years of age together with urbanisation and the increase in the 
prevalence of obesity in many countries worldwide (Wild et al. 2004).
The number of type 2 diabetic patients in Finland was estimated to be near to 
190 000 at the end of 2003. If undiagnosed cases are taken into account, the 
number would be over 400 000 (Reunanen 2004). By 2030, the number of 
diagnosed type 2 diabetes in Finland is expected to rise to 400 000, whereas 
undiagnosed cases may then reach almost one million (Reunanen 2004). The 
prevalence is one of the highest in Europe, almost the same level as in the United 
States, and the main reason for the escalating incidence in Finland is increasing 
obesity (Reunanen 2004).
2.2. Type 2 diabetes and CVD
2.2.1. Type 2 diabetes and the risk of CVD
Type 2 diabetes has been defi ned as: “a state of premature cardiovascular death 
which is associated with chronic hyperglycaemia and may also be associated with 
blindness and renal failure” (Fisher 1998).  The same traditional risk factors for 
CVD are operative in type 2 diabetic as in non-diabetic individuals.  However, 
the effect of any given risk factor on the incidence of CVD is greater in diabetic 
than non-diabetic populations (Stamler et al. 1993).  
The three major vascular beds where atherosclerosis clinically manifests are 
the coronary arteries, lower extremities, and carotid arteries (Beckman et al. 
2002). Patients with diabetes but without previous MI have been reported to 
have a similar risk for subsequent coronary events as nondiabetic patients with 
previous MI (Haffner et al. 1998). Therefore, type 2 diabetes has been defi ned 
as a coronary artery disease risk equivalent by the Adult Treatment Panel III 
(ATPIII) of the National Cholesterol Education Program (NCEP) (Expert 
panel 2001). 
2. REVIEW OF THE LITERATURE
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In addition to the high incidence of coronary heart disease in diabetic patients, 
both short- and long-term case fatality rate after MI is substantially elevated 
(Malmberg et al. 2000, Mukamal et al. 2001).  In the FINMONICA register, 
1-year mortality after fi rst MI for diabetic men was 44 per cent vs. 33 per cent 
in non-diabetic men, and for diabetic women 37 per cent vs. 20 per cent in 
non-diabetic women (Miettinen et al. 1998). The 28-day mortality rate of 
hospitalised MI patients was almost 2-fold in diabetic vs. non-diabetic men and 
3-fold in diabetic vs. non-diabetic women (Miettinen et al. 1998). The 5-year 
mortality rate in diabetic patients has been reported to be up 50 per cent after 
myocardial infarction, which is more than twice the rate of non-diabetic patients 
(Beckman et al. 2002). Mortality is even increased before hospital admission. 
Therefore primary prevention should be strongly emphasized (Haffner 2000). 
For comparison, the 5-year survival rate for any malignant neoplasm diagnosed 
in Finland over the 1999 to 2001 period is predicted to be 55 per cent for men 
and 65 per cent for women (Finnish Cancer Registry 2004). Thus, diabetes is a 
vascular disease with a poor prognosis.
The risk of stroke ranges from 1.5 to a 4-fold increase in type 2 diabetic patients 
(Beckman et al. 2002). The risk of claudication was markedly higher in diabetic 
subjects in the Framingham cohort (Kannel and McGee 1985). The relative risk 
(RR) for lower extremity amputation is over 12-fold higher in type 2 diabetic vs. 
non-diabetic individuals in the US (Beckman et al. 2002). In a Finnish study, 
the risk of amputation in a middle-aged type 2 diabetic cohort followed up for 7 
years was over 5 per cent in both male and female patients (Lehto et al. 1996).
2.2.2. Type 2 diabetes and CVD risk factors
Traditional risk factors, such as hypertension, smoking, and high LDL cholesterol, 
increase CVD risk also in diabetic populations. The presence of microalbuminuria 
has been identifi ed as a CVD risk factor in both type 1 and 2 diabetic patients 
and in the general population (MacIsaacs et al. 2004). Several non-traditional, 
partly overlapping and intertwined, risk factors have been detected during the 
last decade (Table 1). 
Table 1.  Non-traditional risk factors for CVD in type 2 diabetes
Hyperglycaemia Microalbuminuria
Dyslipidaemia Enhanced infl ammation
- elevated triglyceride-rich lipoproteins (TRLs) Endothelial dysfunction
- small dense LDL particles Coagulation abnormalities
- decreased HDL cholesterol  Oxidative stress
- small dense HDL particles Advanced glycation
- postprandial hyperlipidaemia High homocystein level
- remnant particles 
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Chronic hyperglycaemia per se is a risk factor for CVD (Laakso 1999). However, 
the impact of glycaemia is stronger on microvascular than macrovascular end 
points in type 2 diabetes. In the UKPDS (United Kingdom Prospective Diabetes 
Study), each 1 per cent point reduction of HbA1c achieved was associated with 
a reduction of 37 per cent in microvascular complications but with only 14 per 
cent decrease in the incidence of MI (Stratton et al. 2000). These results may 
partly be due to a lack of effi cient treatment options to maintain good glycaemic 
control in the long term.  Nevertheless, the impact of glycaemia in type 2 diabetic 
patients has been demonstrated after coronary angioplasty: optimal glycaemic 
control (HbA1c < 7%) reduced the occurrence of cardiac rehospitalisation and 
recurrent angina by more than half (Corpus et al. 2004).  Potential mechanisms 
of how hyperglycaemia may induce vascular injury include a decrease in the 
bioavailability of nitric oxide (NO) and prostacyclin, increased synthesis of 
vasoconstrictor prostanoids and endothelin, increased production of advanced 
glycation end products (AGEs), excessive oxidative stress, and activation of 
protein kinase C (PKC) (Creager et al. 2003).
Among the traditional CVD risk factors, hypertension is twice as prevalent in type 
2 diabetic as non-diabetic subjects (Stein et al. 1995, Reunanen et al. 2000).  In 
the UKPDS cohort, 32 per cent of men and 45 per cent of women had a diagnosis 
of hypertension at baseline (Turner et al. 1998). The level of systolic blood 
pressure correlated signifi cantly with clinical complications, including CVD, in 
the UKPDS (Adler et al. 2000). A tight control of blood pressure, compared with 
a less tight control, resulted in a 32 per cent decrease in deaths related to diabetes, 
44 per cent decrease in strokes, and 37 per cent decrease in microvascular end 
points in the UKPDS (UK Prospective Diabetes Study Group 1998). A recent 
review on pharmacological and non-pharmacological antihypertensive trials for 
preventing CV complications in diabetic patients included 15 appropriate trials 
with data available for analysis derived from 760 references (Fuller et al 2004). 
The summary odds ratio (OR) for CV mortality from the primary prevention 
trials was 0.64, short-term secondary prevention trials 0.68, and long-term 
secondary prevention trials 0.82. The data demonstrated a treatment benefi t for 
all-cause mortality in the secondary, but not in the primary prevention trials. 
Type 2 diabetes is also accompanied by a multiple derangement of lipid 
metabolism, i.e. diabetic dyslipidaemia. Typical features of diabetic dyslipidaemia 
include elevation of triglyceride-rich lipoproteins (TRL), especially very-low-
density lipoproteins (VLDL), lower HDL cholesterol concentration, and small 
dense LDL particles (Syvänne and Taskinen 1997). 
A recently recognised phenomenon is excessive and prolonged postprandial 
lipaemia (fat intolerance) (Taskinen  2003). This is caused by both increased 
hepatic secretion of VLDL and impaired clearance of VLDL and intestinally 
derived chylomicrons (Krauss 2004). The diurnal triglyceride profi le consists of 
a gradual increase after each meal, the peak concentration being reached between 
dinner and bedtime, and the lowest concentration measured in the morning after 
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an overnight fast. The major component of TRLs after a fat load, approximately 
80 percent, are the VLDL particles (Taskinen 2003). The prolonged retention 
of VLDL and chylomicrons in circulation results in an accumulation of partially 
lipolysed remnant particles, including cholesterol-enriched intermediate-density 
lipoproteins (IDL), which are especially atherogenic (Krauss 2004).  
The increase of TRLs also affects the metabolism of LDL and HDL subclasses 
(Taskinen 2003). The long residence time of the TRLs in circulation favours 
a change of core lipids between both LDL and TRLs and HDL and TRLs, 
leading to triglyceride enrichment of LDL and HDL particles. Hepatic lipase, 
the concentration of which is commonly increased in type 2 diabetes, avidly 
hydrolyses triglyceride enriched LDL and HDL particles, producing smaller 
particles (Taskinen 2003). The small HDL particles are rapidly catabolised and 
cleared from plasma, whereas small dense LDL particles have a longer residence 
time in plasma due to a reduced affi nity for LDL receptors (Krauss 2004).
The trapping of cholesterol-rich, atherogenic lipoproteins within the subendothelial 
space of the vascular wall is one of the initial events in the cascade leading to 
atherosclerosis (Williams 2001). The increased atherogenic potential of small 
dense LDL seem to be related to several properties of these particles: reduced 
LDL receptor affi nity, greater propensity for penetration in the arterial intima, 
increased binding to arterial wall proteoglycans, and susceptibility to oxidative 
modifi cation and glycation (Taskinen 2003, Krauss 2004). 
HDL particles are important in reverse cholesterol transport, i.e. transport of 
cholesterol from peripheral tissues via plasma to the liver. HDL particles have 
additional functions including, among other actions, anti-thrombotic and 
antioxidant effects, amelioration of abnormal vasoconstriction by stimulation of 
nitric oxide (NO) production, and inhibition of adhesion of monocytes to the 
endothelium (Barter et al. 2003). The cardioprotective effects of HDL particles 
are decreased in type 2 diabetes, due to reduced numbers of HDL particles and 
to structural changes in the HDL particles (Taskinen 2003). 
Land-mark lipid-lowering trials – the 4S (Simvastatin Scandinavian Survival 
Study), CARE (Cholesterol And Recurrent Events), AFCAPS/TexCAPS (Air 
Force/Texas Coronary atherosclerosis Prevention Study), and LIPID (Long term 
Intervention with Pravastatin in Ischaemic heart Disease) – have demonstrated 
that lowering of LDL cholesterol with HMG-CoA reductase inhibitors reduces the 
rate of coronary events in diabetic subgroups by 19 to 55 per cent (Kreisberg and 
Oberman 2002). The Heart Protection Study (HPS) included a subgroup of 5963 
diabetic patients, among whom simvastatin intervention reduced the risk for major 
vascular events (including major coronary events, stroke, and revascularisation) 
by approximately one quarter (Heart Protection Study Collaborative Group 
2003). The Collaborative Atorvastatin Diabetes Study (CARDS) (Colhoun et 
al 2004) assessed the effectiveness of atorvastatin for primary prevention of CV 
events in an entirely type 2 diabetic patient cohort (N = 2838). The event rate 
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was substantially reduced (by 37 percent), and the effect was not related to pre-
treatment cholesterol levels.
Fibrates correct most abnormalities in diabetic dyslipidaemia: fi brates lower 
triglycerides, increase HDL cholesterol, increase the clearance of VLDL and 
remnant lipoproteins, shift LDL particle size distribution to a larger form, 
and decrease production of small dense HDL (Watts and Dimmitt 1999). 
Consequently, fi brates should theoretically be the best treatment option for 
diabetic dyslipidaemia (Barter 2001). 
In a post-hoc analysis of a small diabetic subgroup of the Helsinki Heart Study, 
gemfi brozil reduced CHD events by 68 per cent, but the result was statistically 
non-signifi cant due to the small number of patients (Frick et al. 1987). The DAIS 
(Diabetes Atherosclerosis Intervention Study) demonstrated angiographically 
documented regression of coronary atherosclerosis by fenofi brate intervention 
(Diabetes Atherosclerosis Intervention Study Investigators 2001). The Veterans 
Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) used gemfi brozil 
for secondary prevention. In that study, gemfi brozil reduced CVD death, stroke 
and MI by one third in the diabetic subgroup (Rubins et al. 2002). Interestingly, 
at the VA-HIT, baseline insulin resistance predicted CVD events and the benefi t 
of fi brate intervention more powerfully than HDL cholesterol or triglyceride levels 
(Robins et al. 2003). The FIELD (Fenofi brate Intervention and Event Lowering 
in Diabetes) study and the ACCORD (Action to Control Cardiovascular Risk 
in Diabetes) (Prisant 2004) study will demonstrate if fi brates are actually even 
more effective than statins in the prevention of CVD in diabetic subjects.
2.3. The metabolic syndrome
2.3.1. Defi nitions and prevalence of the metabolic syndrome
The metabolic syndrome was recognized in the late 1980’s, then called the 
Syndrome X (Reaven 1988). Rapidly accumulating literature has addressed the 
metabolic syndrome, recognizing it as both a cardiovascular risk factor and a 
predictor of type 2 diabetes (Nesto 2003, Grundy 2004). 
The metabolic syndrome has been defi ned by various criteria (Grundy et al 
2004a), the main of which are the WHO defi nition (WHO 1999) and the 
NCEP (National Cholesterol Education Program) criteria, also called the ATP 
III (Adult Treatment Panel III) criteria (Expert Panel 2001) (Table 2).
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WHO defi nition
Diabetes/IFG/IGT + at least 2 
of the following:
NCEP criteria
3 or more of the following criteria:
1. Insulin resistance (under hyper-
insulinaemic, euglycaemic conditions, 
glucose uptake < lowest quartile of 
background population)
1. Abdominal obesity: 
Waist circumference  
> 102 cm in men,  
> 88 cm in women
2. Raised arterial pressure ≥ 140/90 2. Hypertriglyceridemia > 1.69 mmol/l
3. Raised P-triglycerides (≥ 1.7 mmol/l) 
and/or low HDL cholesterol 
(< 0.9 mmol/l in men, < 1.0 mmol/l 
in women)
3. Low HDL cholesterol < 1.04 mmol/l 
in men, < 1.29 mmol/l in women
4. Central obesity: 
(males: WHR > 0.90; females: > 0.85) 
And/or BMI > 30kg/m2
4. High blood pressure ≥ 130/85
5. Microalbuminuria (UAER ≥ 20μg/
min or albumin : creatinine ratio 
≥ 30mg/g)
5. High fasting glucose ≥ 6.1 mmol/l
Table 2. WHO and NCEP defi nitions of the metabolic syndrome.
 
Both sets of criteria are specifi c tools to detect low insulin sensitivity among 
non-diabetic subjects, although the WHO criteria are more sensitive than the 
NCEP criteria (Hanley et al. 2003). Similar comparisons between the sensitivity 
of the two criteria sets to detect insulin resistance have not been performed in 
type 2 diabetic cohorts. Nevertheless, clustering of risk factors typical of insulin 
resistance have been associated with extreme insulin resistance also among type 
2 diabetic patients (Haffner et al 2003).
Two more criteria sets for the diagnosis of insulin resistance syndrome, including 
features from both WHO and NCEP criteria, have been suggested by the 
American Association of Clinical Endocrinologists and by the European Group 
for the Study of Insulin Resistance (EGIR) (reviewed in Grundy et al. 2004a). 
The key difference from the NCEP criteria are that both of these criteria sets are 
totally founded on insulin resistance.
Other features of the metabolic syndrome not mentioned in the defi nitions 
are hyperuricaemia and gout, non-alcoholic fatty liver disease (NAFLD), 
abnormalities in fi brinolysis and coagulation, the polycystic ovary syndrome, signs 
of chronic infl ammation, endothelial dysfunction, and increased sympathetic 
activity (Isomaa 2003). 
The estimated prevalence of the metabolic syndrome depends on the population 
and the defi nition of the metabolic syndrome and its components. In a cross-
sectional US population sample collected over the 1988-1994 period, the age-
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adjusted prevalence among 8608 participants aged ≥20 years was 23.9 per cent 
using NCEP criteria and 25.1 per cent using WHO criteria. In some subgroups 
the difference was more marked. For example, in African-American men the 
prevalence was 24.9 per cent according to WHO defi nition criteria and only 
16.5 per cent using the NCEP defi nition criteria (Ford and Giles 2003). In the 
year 2000, about 47 million US residents had the metabolic syndrome (Ford et 
al. 2002). The prevalence of the metabolic syndrome increases with age and is 
highest in the elderly population. The increase of obesity in the population is 
paralleled by a rising incidence of the metabolic syndrome also in middle-aged 
individuals, and even in youths (Grundy et al 2004b, Weiss et al. 2004).
In the Botnia study, metabolic syndrome as defi ned by the WHO criteria was 
present in ~ 10 per cent of subjects with NGT, ~ 50 per cent in subjects with IGT/
IFG, and ~ 80 per cent of subjects with type 2 diabetes. (Isomaa et al. 2001). 
In another Finnish study (Lakka et al. 2002), the presence of the metabolic 
syndrome in middle-aged men was 14.2 per cent using the WHO criteria and 
8.2 per cent using the NCEP criteria. Recently, the population-based FINRISK 
cohort (aged 45-64 years) and the glucose-intolerant Diabetes Prevention Study 
(DPS) cohort (aged 40-65 years) where analysed using modifi ed WHO criteria 
for metabolic syndrome (Ilanne-Parikka et al. 2004). Metabolic syndrome was 
present in ~ 40 per cent of men and ~20 per cent of women in the FINRISK 
cohort. The extremely high prevalence in men in the FINRISK cohort was mainly 
due to abdominal obesity: more than three-quarters of men had a WHR > 0.9. 
Not surprisingly, in the DPS cohort the prevalence of the metabolic syndrome 
was 75 per cent.
2.3.2. The metabolic syndrome as a predictor of CVD and 
type 2 diabetes 
Obviously, as the metabolic syndrome is a cluster of several cardiovascular risk 
factors, it carries a great risk of cardiovascular disease. In the Framingham 
database, the metabolic syndrome accounted for approximately one fourth of 
cardiovascular morbidity (Grundy et al. 2004a). Hyperinsulinaemia, which is 
among non-diabetic subjects a marker of insulin resistance, was associated with 
an increased CHD risk over a 22-year follow-up in the Helsinki Policemen study 
(Pyörälä et al. 1998).  In the Botnia study, subjects with the metabolic syndrome 
had a 3-fold increased risk for CHD and stroke, 5-6-fold increased risk of 
cardiovascular death, and increased all-cause mortality (Isomaa et al. 2001). In 
the San Antonio Heart Study, where a population cohort was studied between 
1984-1988 and followed up 6 - 7 years later, insulin resistance as calculated 
by the homeostasis model (HOMA IR) was associated with an increased CVD 
incidence independently of several cardiovascular covariates (Hanley et al. 2002). 
In Finnish men, insulin resistance and the metabolic syndrome predicted CHD 
events and both CV and all-cause mortality (Kuusisto et al. 2001, Lakka et al. 
2002). In a Dutch study on a cohort of patients with recently diagnosed CHD, 
the metabolic syndrome was present in 45 per cent, and associated with increased 
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IMT, albuminuria, and ankle brachial pressure index (Olijhoek et al. 2003). 
In the Verona diabetes complications study, HOMA IR was an independent 
predictor of prevalent and incident CVD among type 2 diabetic patients during 
a follow-up of 4.5 years (Bonora et al. 2002). Trevisan et al. (1998) followed 
mortality in relation to the components of the metabolic syndrome for a mean 
of 7 years in a population-based Italian cohort of approximately 20 000 men 
and women. In that study, an increasing number of features of the metabolic 
syndrome was associated with increased incidence of CV and all cause death in 
both genders.  
Nine studies on the association between insulin resistance and the risk of stroke 
were reviewed by Kernan et al. (2002). Six of these studies were methodologically 
sound and provided substantial evidence that insulin resistance is associated with 
a 60 per cent to 160 per cent increased risk of stroke.
The metabolic syndrome not only accompanies, but also precedes and predicts, 
type 2 diabetes (Yki-Järvinen 2000, Kekäläinen et al. 1999, Hanson et al. 2002). 
In the Framingham cohort, the presence of the metabolic syndrome at baseline 
as defi ned by NCEP criteria was considered to be a powerful predictor of newly-
onset diabetes, accounting for almost half of the risk for diabetes (Grundy et 
al. 2004a). The San Antonio Heart Study investigators compared three options 
to predict the onset of type 2 diabetes: 1) IGT detected by the OGTT, 2) the 
presence of the metabolic syndrome by the NCEP criteria, and 3) the presence 
of the metabolic syndrome according to a modifi ed version of the WHO criteria 
(without OGTT). Of the three, IGT was the best predictor: 43 per cent predictive 
value vs. 31 per cent by the NCEP criteria and 30 per cent by the modifi ed WHO 
criteria (Lorenzo et al. 2003). This result indicates that the OGTT remains 
valuable in screening for diabetes risk. Interestingly, in a study among non-
diabetic American Indians, HOMA IR and the metabolic syndrome at baseline 
were associated with an increased the risk for developing diabetes, but did not 
predict CVD independently of other CV risk factors (Resnick et al. 2003). 
2.3.3. Obesity, infl ammation, and the metabolic syndrome 
During the last decade, new discoveries elucidated interactions between the 
adipose tissue and the pathophysiology of the metabolic syndrome, and their 
links to infl ammation, endothelial dysfunction, diabetes, and atherosclerosis. 
Insulin resistance is regarded as the fundamental abnormality behind the 
metabolic syndrome (Haffner et al.1992). Recent data suggest that a high 
amount of fat and a derangement of the adipose tissue metabolism are in fact 
the primary factors determining the development of insulin resistance and 
other components of the metabolic syndrome (Ruan and Lodish 2004).  In 
the Insulin Resistance Atherosclerosis Study (IRAS), the strongest predictor 
of the metabolic syndrome was waist circumference, thus abdominal obesity 
may precede the development of the other manifestations/components of the 
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metabolic syndrome (Palaniappan et al. 2004). Likewise in the San Antonio 
Study, one third of subjects with both a large waist circumference and high BMI 
developed the metabolic syndrome during a 8 years’ follow-up. Adjusting for 
fasting insulin concentrations had only a minor effect on the predictive value of 
the anthropometric indices (Han et al. 2002b).
The crucial role of the fat mass does not rule out the importance of heritability 
in the development of the metabolic syndrome. Environmental factors, i.e. 
the obesity epidemic due to the lack of physical exercise and increased caloric 
intake, are obviously responsible for the current increase in the incidence of the 
metabolic syndrome worldwide. Yet, the predisposition to gain weight is highly 
individual and to a great extent determined by genetic factors (Speakman 2004, 
Bouchard and Perusse 1993).
As early as the late 1980’s, adipose tissue was found to be involved in the 
metabolism of sex steroids and to produce an endocrine factor called adipsin 
(Flier et al 1987, reviewed in Kershaw and Flier 2004). A variety of adipocyte-
derived proteins with humoral functions have been detected, acting both in 
an autocrine/paracrine fashion and also at a systemic (endocrine) level.  These 
include cytokines and cytokine-related proteins, such as leptin, tumour necrosis 
factor α (TNFα), and IL-6 (interleukin -6), factors involved with fi brinolysis, 
such as plasminogen activator inhibitor -1 (PAI-1) and tissue factor, or with 
the complement system, as well as enzymes involved in steroid metabolism, etc. 
(Kershaw and Flier 2004). Furthermore, fat cells express receptors that allow 
them to respond to afferent signals from traditional hormone systems and 
the central nervous system. Thus adipose tissue is actively involved in energy 
metabolism, neuroendocrine function, and immune function.
Adiponectin is the only adipokine that is known to increase insulin sensitivity 
(Bays et al. 2004). In animal studies, the decrease of adiponectin has preceded 
the development of insulin resistance and obesity (Kershaw and Flier 2004). 
Low levels of adiponectin are associated with type 2 diabetes and obesity, 
correlate inversely with insulin resistance, and are predictive of the development 
of type 2 diabetes (Rajala and Scherer 2003, Chandran et al. 2003, Krakoff 
et al. 2003, Bays et al. 2004). Improving insulin sensitivity by weight loss or 
insulin-sensitising medical treatment increases adiponectin levels (Kershaw and 
Flier 2004).  A low level of adiponectin has been shown to be associated with the 
prevalence of coronary artery disease and to predict the occurrence of myocardial 
infarction (Nakamura Y et al. 2004, Pischon et al. 2004). 
Resistin is an adipocyte-derived protein that has been shown to cause insulin 
resistance when injected in healthy animals (Bays et al. 2004). Yet, subsequent 
human studies have failed to provide a consistent link between resistin expression 
or resistin concentrations with obesity or insulin resistance (Kershaw and Flier 
2004). 
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Leptin is secreted by the adipose tissue in direct proportion to the adipose tissue 
mass (Kershaw and Flier 2004). Leptin was initially viewed as an antiobesity 
hormone, but later research has demonstrated that the physiological role of leptin 
is to act as a metabolic signal of energy suffi ciency. Caloric restriction and weight 
loss are accompanied by a rapid decrease in circulating leptin concentration, 
associated with increased appetite and a decline in energy expenditure. In obese 
subjects the leptin concentration is elevated due to increased fat mass, but these 
supraphysiological leptin levels fail to suppress appetite, consistent with a state of 
leptin resistance (Kershaw and Flier 2004).  
Chronic subclinical infl ammation is enhanced in the metabolic syndrome (Festa 
et al. 2000, Hak et al. 2001, Fröhlich et al. 2000, Fernández-Real and Ricart 
2003, Pickup 2004). The degree of infl ammation is associated with the amount 
of fat mass and central adiposity (Lyon et al. 2003). For example, circulating 
levels of C-reactive protein (CRP) correlate with insulin resistance (Festa et al. 
2000, Lemieux et al. 2001) and the amount of adipose tissue (Hak et al. 1999, 
Festa et al. 2001, Lemieux et al. 2001). 
The major cytokine mediator of the acute-phase response, IL-6, is highly 
expressed and secreted into the circulation by the adipose tissue (Bays et al. 
2004). As much as 30 per cent of circulating IL-6 is derived from fat tissue in 
obese individuals  (Mohamed-Ali et al. 1997). IL-6 stimulates hepatic CRP 
production (Lemieux et al. 2001, Lyon et al. 2003) and may also secondarily 
augment CRP secretion by its infl ammatory-inducing actions (Bays et al. 2004). 
IL-6 levels are increased in type 2 diabetic patients and are correlated with the 
severity of glucose intolerance (Bays et al. 2004). The complex mechanisms as 
to how the insulin-resistant state might induce increased IL-6 production have 
been reviewed by Fernández-Real and Ricart (2003). Adipose tissue is infi ltrated 
by macrophages in obese rodents; thus obesity-induced insulin resistance may be 
mediated by macrophage-related infl ammatory reactions in addition to adipocyte 
actions (Xu et al. 2003).
2.4. Endothelial function and its markers
The vascular endothelium physiologically maintains vascular homeostasis by 
synthesizing and releasing vasoactive substances in reaction to haemodynamic 
forces and blood borne stimuli (De Caterina 2000, Szmitko 2003).  Functional 
properties of the endothelium include the regulation of vascular tone, as well 
as active control of haemostasis, leukocyte adhesion and migration, endothelial 
permeability, medial smooth muscle cell growth, and structure of subendothelial 
matrix (De Caterina 2000, Sica 2000).  A healthy endothelium also exerts 
antioxidant and anti-infl ammatory effects (Bonetti et al. 2003). No universally 
accepted defi nition exists for endothelial dysfunction. Disruption of the 
balance in any or all of the diverse functions of the endothelium including: 
the disequilibrium between vasodilatation and vasoconstriction, fi brinolytic and 
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thrombotic properties, derangement of antiadhesive properties, or disturbance 
in permeability – indicate endothelial dysfunction (Mattz and Andriantsitohaina 
2003). Table 3 presents factors that participate in the regulation of endothelial 
functions (modifi ed from Calles-Escandon and Cipolla 2001).
Table 3. Endothelial functions and examples of mediators.
Vasoconstriction Endothelin, angiotensin II, thromboxane A2
Vasodilatation Nitric oxide, bradykinin
Growth stimulation Platelet-derived growth factor, fi broblast growth factor, 
insulin-like growth factor I, endothelin, angiotensin II
Infl ammation Vascular cell adhesion molecule 1, intercellular adhesion 
molecule 1, selectins, tumour necrosis factor α
Haemostasis Tissue plasminogen activator, plasminogen activator 
inhibitor 1, prostacyclin
 
The insulin-resistant state is accompanied by endothelial dysfunction, leading to 
increased leukocyte adherence and penetration in the arterial intima, accumulation 
of atherogenic lipoprotein particles in the intima, enhanced thrombosis, as well 
as to a decline in endothelium-dependent vasodilatation (De Caterina 2000, 
Wheatcroft et al. 2002,Yki-Järvinen et al. 2003). 
Insulin reduces the stiffness of arteries (Westerbacka et al. 1999), and this action 
of insulin is inversely related to insulin resistance and obesity (Westerbacka et al. 
2001). Insulin normally increases the production of NO (Kuboki et al. 2000). 
In type 2 diabetes, endothelium-dependent vascular relaxation is impaired due 
to decreased NO bioactivity in the vessel wall. Indeed vascular endothelial 
dysfunction can be regarded a feature of the insulin resistance syndrome (Yki-
Järvinen 2003). Invasive methods for endothelial function testing (Ganz and 
Vita 2003) are laborious and timeconsuming. Results obtained by non-invasive 
methods remain partly disputable.
The healthy vascular endothelium is resistant to circulating infl ammatory reactants 
and cells (Libby et al. 2002). Infl ammation of the endothelial monolayer leads 
to secretion of cell adhesion molecules (CAM) that have an autocrine/paracrine 
effect on the endothelium itself, the surrounding smooth muscle cells, and the 
blood cells (Calles-Escandon and Cipolla 2001, Hansson 2001). For example, 
selectins mediate leukocyte recruitment and adhesion at sites of infl ammation 
on the endothelium (Price and Loscalzo 1999). The second major group of 
adhesion molecules belong to the immunoglobulin supergene family, including 
among others ICAM-1 and VCAM-1 (Blann and Lip 2000). 
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The initiation of atherosclerosis requires activation of the endothelium to 
express CAMs. Figure 1 illustrates the initial steps of atheroma formation: 1) 
rolling of monocytes on the endothelial surface induced by selectins, 2) adhesion 
of monocytes to the endothelial layer through interactions with CAMs, 3) 
penetration of the monocytes to the intima governed by chemotactic factors 
(e.g. monocyte chemotactic protein-1, MCP-1), 4) differentiation of monocytes 
into macrophages induced, among others, by macrophage colony stimulation 
factor (M-CSF), and 5) uptake of modifi ed lipoproteins in the macrophage by 
way of scavenger receptors, a process regulated by cytokines such as TNFα and 
interleukins, 6) fi nally leading to foam-cell formation. 
Figure 1. Endothelial dysfunction leading to initiation of atherosclerosis. 
Modifi ed from Li and Glass 2001.
 
Local infl ammatory reactions are also involved in subsequent smooth muscle 
cell (SMC) proliferation, atheroma formation, thinning of the fi brous cap of the 
atheroma, leading to plaque rupture, and thereafter thrombosis at the site of the 
rupture (Hansson 2001, Libby et al. 2002).  
2.5. Infl ammation in CVD and diabetes
The importance of systemic low-grade infl ammation in the initiation and 
development of atherosclerosis as well as acute CV events has been extensively 
studied and fi rmly established (Ross 1999, Hansson 2001, Libby et al. 2002). 
Several cytokines and acute-phase reactants have been shown to be associated 
with and predict cardiovascular disease, among others CRP, IL-6, serum 
amyloid A (SAA), fi brinogen, white blood cell count, D-dimer, plasminogen 
activator, TNFα, lipoprotein phospholipase A2, interleukin-18, metalloproteinase 
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PAPP-A, and secretory nonpancreatic phospholipase A2 type IIA (sPLA2) 
(Pearson et al. 2003, Fichtlscherer et al. 2004, Hurt-Camejo et al. 2001). 
Among a wide range of biomarkers CRP is considered to be the most applicable 
for clinical use. In several studies, CRP has actually predicted cardiovascular 
disease better than other infl ammatory biomarkers including CAM, TNFα, 
and IL-6, or even LDL cholesterol and other lipoprotein levels  (Fichtlscherer 
et al.2004). In the general population, the level of CRP has consistently 
predicted incident MI, stroke, peripheral arterial disease, sudden cardiac death, 
and recurrent ischaemia and death in patients with angina and acute coronary 
symptoms (Ridker 2003). 
Mechanisms as to how CRP might induce atherogenesis include binding to lipids, 
opsonising native LDL to macrophages, reducing the production of endothelial 
nitric oxide synthase (e-NOS) and decreasing NO bioavailability (Fichtlscherer et 
al. 2004), activating CAM expression by endothelial cells, and inducing MCP-1 
production (Yeh 2004). Danesh et al. (2000) compared CRP levels in men who 
died from CHD or suffered a non-fatal MI with those of men who remained 
CHD free. The odds ratio of CHD was >2 in men in the top tertile of CRP 
when adjusting for confounders.  However, the authors additionally conducted 
a meta-analysis. According to this it still remains open if CRP is an independent 
risk factor for CVD (Danesh et al 2000). The AHA recommendations state that 
the best, but so far inconclusive, evidence supports the use of CRP in clinical 
assessment of CV risk (Pearson et al. 2003). 
Systemic infl ammation is also associated with atherogenic changes of lipoprotein 
metabolism: hypertriglyceridaemia, elevated TRLs, small dense LDL, sphingolipid-
enriched lipoproteins, and decreased HDL (Khovidhunkit et al. 2000). HDLs 
exert anti-infl ammatory effects by inhibiting expression of MCP-1 and CAMs in 
endothelial cells (Barter P 2004, Calabresi et al. 2003). In insulin-resistant states 
the lowering in HDL cholesterol levels leads to a decline in its protective action 
against endothelial infl ammation. One link between systemic infl ammation 
and atherogenesis may be secretory phospholipase A2 IIA (sPLA2), an acute-
phase reactant, which is able to deplete the phospholipid layer of LDL thus 
rendering LDL particles smaller, denser, and more proatherogenic (Hurt-Camejo 
et al. 2000). Small LDL particles are associated with endothelial dysfunction 
(Vakkilainen et al. 2000). 
Elevated concentrations of infl ammatory markers have been shown to precede 
the onset of clinical diabetes in several studies (Pickup 2004). Among over 32 
000 participants in the Nurses’ Health Study, CRP levels were signifi cantly 
associated with the risk of developing diabetes during a 10 year follow-up (Hu 
et al. 2004). In the Atherosclerosis Risk in Communities (ARIC) study, IL-6 
independently predicted incident type 2 diabetes, whereas the predictive value of 
CRP disappeared after adjusting for adiposity, fasting glucose and insulin levels 
(Duncan et al. 2003). In the Mexico City Diabetes study, CRP was a signifi cant 
2. REVIEW OF THE LITERATURE
225333Leinonen.indd   26 1.5.2005   10:53:57
27
predictor for the development of the metabolic syndrome – described as incident 
dyslipidaemia or hypertension or diabetes - only in men, but not in women 
(Han et al. 2002 a). Using factor analysis in the IRAS cohort, Hanley and co-
workers could identify three underlying factors: a “metabolic”, “infl ammation”, 
and “blood pressure” factor, each of which signifi cantly predicted future diabetes 
(Hanley et al. 2004). 
During endothelial activation, the plasma concentrations of CAMs rise due to 
increased endothelial production and/or shedding of CAMs into the circulation 
(Price and Loscalzo 1999). In several studies the concentrations of CAMs 
have correlated with traditional CV risk factors, acute coronary syndromes, and 
subsequent progression of atherosclerosis (reviewed by Bonetti et al. 2003). 
Elevated levels of CAMs have been detected in diabetic patients and individuals 
with insulin resistance or at high risk for developing type 2 diabetes (Blann and 
Lip 2000, Calles-Escandon and Cipolla 2001). However, the prognostic value 
of CAM as predictors of CVD remains controversial (Malik et al. 2001, Bonetti 
et al 2003). A handful of prospective studies have suggested that infl ammation 
and/or endothelial dysfunction predict CVD risk in type 2 diabetes (Jager et al. 
1999, Jager et al. 2000, Saito et al. 2000, Stehouwer et al. 2002, Pickup and 
Mattock 2003).
As yet, it is not settled if increased acute-phase reaction and endothelial dysfunction 
are causally linked to increased CVD risk in type 2 diabetes. Infl ammation 
seems to be a common antecedent of both atherosclerosis and diabetes. Insulin 
resistance independently predicts CVD in type 2 diabetic patients (Bonora et al. 
2002). On the other hand, CRP correlates with the severity of the metabolic 
syndrome (Fröchlich et al. 2000). The temporal relationship between the 
initiation of infl ammation and insulin resistance still remains unknown.
2.6. The IGF system in CVD and diabetes
2.6.1. The IGF axis
The insulin-like growth factor family (IGF) contains three peptide hormones 
– (pro)insulin, IGF-I and IGF-II, which share homology in their amino acid 
sequence (Le Roith 1997). Circulating levels of IGF-I and IGF-II are determined 
primarily by their production in the liver. IGFs are bound to IGF-binding proteins 
(IGFBPs), which are mainly of hepatic origin, and which also critically modulate 
the cell response to IGFs (Bayes-Genis et al. 2000). In addition, many cells in the 
body (including vascular smooth muscle cells) synthesize IGFs and IGFBPs in an 
autocrine/paracrine manner (Bayes-Genis et al. 2000, Frystyk et al. 2002). 
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Figure 2. The IGF axis
Growth hormone (GH) stimulates the 
hepatic production of insulin-like growth 
factor I (IGF-I), insulin-like growth 
factor binding protein 3 (IGFBP-3) and 
acid-labil subunit (ALS). IGF-I exerts 
negative feedback on GH secretion. 
IGF-I bioactivity in plasma is regulated 
e.g. by the relative amount of IGF-I 
bound to an inactive complex of IGFBP-
3 and ALS, and to IGFBP-1 and other 
IGFBPs. Insulin regulates (suppresses) 
the production of IGFBP-1 in the liver.
IGFs bind to a membrane receptor, which is very similar to the insulin receptor 
(Le Roith 1997). The main reservoir of IGF-I is the inactive trimeric complex 
with IGFBP-3 and a liver-derived glycoprotein called acid-labil subunit (ALS), 
binding more than 95 per cent of the IGF in serum (Rehman HU 2000). IGFBP-
1 exhibits diurnal variation, in contrast to the more stable IGFBP-2 and -3. It is 
also one of the major regulators of IGF availability in plasma (Rabkin SW 1996). 
Insulin regulates IGF-I bioavailability by suppressing hepatic IGFBP-1 production, 
resulting in increased circulating free IGF-I concentration (Mohamed-Ali et al. 
1999). Insulin circulates at picomolar (10-12) concentrations affecting mainly 
the liver, muscle and adipose tissue, whereas the IGFs circulate at nanomolar 
(10-9) concentrations and have a broad range of actions in the body (Le Roith 
1997).  IGF-I effects may be mediated through high-affi nity binding to its 
own receptor, or through low-affi nity binding to insulin receptors (Frystyk et 
al. 2002). Thus, the end result of IGF-I mediated biological functions depend 
on the receptor, i.e. differences in post-receptor signalling of IGF-I and insulin 
receptors.  The effects that IGF-I causes by low-affi nity binding to insulin 
receptors may be relevant due to the high plasma concentrations of IGF-I 
compared with insulin levels.
2.6.2. IGF-I and IGFBP-1 in diabetes and CVD
IGFs mediate most of the effects of growth hormone (Rehman 2000). The 
multiple physiological effects that IGF-I exerts on the vasculature have been 
recently reviewed (Delafontaine et al. 2004).  IGF-I has endocrine and autocrine/
paracrine effects on blood vessels, including proliferative, hypertrophic, cell 
survival, vasomotor, and metabolic effects, which are modulated by IGFBPs. 
Growth hormone and/or IGF-I have been shown to be implicated in the 
development of diabetic micro- and macrovascular complications in several 
studies reviewed by Rehman (2000). Yet, the role of IGF-I and GH in diabetic 
complications remains controversial (Frystyk et al. 2002). Paradoxically, 
cardiovascular risk is increased in both acromegaly (Colao et al. 2001) and 
growth hormone defi ciency (McCallum et al. 2002). 
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Levels of IGFBP-1 are increased in type 2 diabetic patients (Clauson et al. 1998), 
and decreased in subjects with impaired glucose tolerance in comparison with 
healthy subjects (Heald et al. 2001). As insulin regulates (suppresses) hepatic 
IGFBP-1 production, changes in IGFBP-1 at least partly mirror the change in 
insulin levels during the deterioration of glucose tolerance, i.e. the compensatory 
hyperinsulinaemia in subjects with IGT and the following decline in insulin 
secretion in type 2 diabetes. IGFBP-1 levels are inversely correlated with several 
cardiovascular risk factors, such as high TG, low HDL cholesterol, hypertension, 
insulin, proinsulin, and obesity in both type 2 diabetic and healthy subjects 
(Gibson et al. 1996, Janssen et al. 1998, Mohamed-Ali et al. 1999, Heald et al. 
2001). IGFBP-1 is also strongly directly related to insulin sensitivity (Mohamed-
Ali et al. 1999, Ricart and Fernández-Real 2001).
2.7.  Intima-media thickness (IMT) and CVD and 
diabetes
Non-invasive imaging techniques to detect preclinical atherosclerosis have been 
developed during the last decades to identify individuals at an increased risk 
for clinical CVD. Such techniques are used to monitor the vascular response 
to different treatment modalities, i.e. to serve as a surrogate end-point in 
cardiovascular research. 
The most commonly used non-invasive method has been the B-mode ultrasound 
scanning of carotid and/or femoral artery intima-media thickness (IMT) 
developed in late 1980s (Poli et al. 1988, reviewed by Salonen and Salonen 1993, 
Lonn 1999, Cheng et al. 2001, O’Leary and Polak 2002, Bots et al. 2003). 
The IMT is defi ned by the two parallel echogenic lines which correspond to 
the interfaces between lumen/intima and media/adventitia (see Methods, 5.3.1. 
Intima-media thickness (IMT), Figure 3). The thickness of the echogenic line 
next to the vascular lumen added to the thickness of the adjacent dark layer 
together compose the IMT both at the near wall and at the far wall.
 
The relation between ultrasonic scanning and histological IMT measurement 
has been examined in several studies (reviewed by Cheng et al. 2002). Ultrasonic 
estimation gives a slightly higher IMT result than histological samples possibly 
due to post-mortem shrinkage and fi xation-caused contraction in the latter 
method. The near wall sonographic measurement corresponds to approximately 
80 per cent of the histological thickness, and a difference of 0.02 mm is present 
when comparing the near and far wall measurements (Kanters et al. 1997). 
However, this difference is constant across all measurements. Therefore adding 
near wall measurement in the protocol has resulted in smaller variation across
 the measurements (Kanters et al. 1997). 
The reproducibility of measurements and their association with CVD has been 
similar for the near and far wall measurements (Bots et al. 2003). The common 
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carotid artery (CCA) is the most readily available part of the carotid artery and 
therefore examined in most studies. The internal carotid artery (ICA) and the 
carotid bulb (CB) have been studied less frequently, because they are not as 
close or as parallel to the skin and are therefore more diffi cult to scan (Kanters 
1997). The association of increased IMT with clinical CVD has been stronger, if 
the carotid scans were bilateral and included multiple parts of the carotid artery 
(Kanters et al. 1997, Bots et al. 2003). 
The validity of the results depends on the repeatability of the scans and reading of 
scans. The repeatability can be increased by proper training, using one individual 
scanner and reader, and by using computerised edge detection techniques when 
reading the scans (Bots et al. 2003).
IMT increases with age and is generally thicker in men than in women (Cheng et 
al. 2002). The growth rate of IMT depends on the background population (Fathi 
and Marwick 2001). For example in a population cohort in Eastern Finland, 
the mean increase was 0.12 mm in two years (Salonen and Salonen 1990). 
The differences in the growth rates between various populations are obviously 
determined by the prevalence of risk factors within the populations, as well as 
their diverse genetic backgrounds.  Risk factors predicting IMT in the general 
population include age, gender, blood pressure, total and LDL cholesterol, low 
HDL cholesterol, and smoking (Salonen and Salonen 1990, Salonen and Salonen 
1991, O’Leary et al. 1996, Crouse et al. 1996, Lakka et al. 1999, Espeland et al. 
1999), genetic factors (Cattin et al. 1997, Kakko et al 2000, Zannad and Benetos 
2003, Jerrard-Dunne et al. 2003), LDL particle size (Skoglund-Andersson et al. 
1999, Hulthe et al. 2000), postprandial hyperlipidaemia (Boquist et al. 1999), 
fasting and postprandial hyperglycaemia (Yamasaki et al. 1995, Hanefeld et al. 
2000, Temelkova-Kurktschiev et al. 2000, Gerstein et al. 2003), the amount 
and distribution of body fat (Bonora et al. 1997, Takami et al. 2001), and socio-
economic factors (Lamont et al. 2000). The correlation of IMT with CV risk 
factors and events has been variable between different carotid segments (Crouse 
et al. 1996, Bots et al. 1997, Rosfors S et al. 1998, Ebrahim et al. 1999).
Studies using IMT as a surrogate end point for CVD have been extensively 
reviewed (Cheng et al. 2002, Redberg et al. 2002). Several large studies 
(reviewed by Cheng et al. 2001, Fathi and Marwick 2001, O´Leary and Polak 
2002, Bots et al. 2003) have demonstrated that increased IMT is associated with 
prevalent CVD and predicts future CVD events such as myocardial infarction 
and stroke in the general population. Carotid IMT and its progression rate have 
correlated with and predicted coronary events, claudication, and stroke in several 
studies (Cheng et al. 2002). In the Rotterdam study, though, baseline IMT 
did not substantially add to a calculated risk for CAD when adjusting for other 
common coronary risk factors (Van Popele et al. 2001). In lipid-lowering trials, 
attenuation of intima-media thickening has accompanied reduction in clinical 
CVD incidence (Salonen et al. 1995, Mercuri et al. 1996, Bots et al. 2003).  
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IMT has nearly always been thicker in type 2 diabetic patients than in non-
diabetic subjects (Yamasaki et al. 1995, Yamamoto et al. 1997, Mykkänen et 
al. 1997, Temelkova-Kurktschiev et al. 1999, Goff et al. 2000, Mohan et al. 
2000, Bonora et al. 2000). In the RIAD study, post-challenge hyperglycaemia 
was related more strongly than fasting glucose to IMT (Hanefeld et al. 2000). 
In the IRAS (Haffner et al. 2000), IMT was greatest in diabetic subjects with 
coronary artery disease (CAD) and thinnest in non-diabetic subjects without 
CAD.  Diabetic individuals without CAD had slightly, but not signifi cantly, 
thicker mean IMT than non-diabetic patients with CAD. In contrast, in elderly 
Finnish men (70-89 years), glucose tolerance status was not related to carotid 
IMT (Tuomilehto et al. 1998). 
The determinants of IMT among type 2 diabetic patients have been variable. 
The most constant factors associated with IMT are age, duration of diabetes, 
and blood pressure. Microalbuminuria has been shown to correlate with IMT in 
both non-diabetic and diabetic patients (Mykkänen et al. 1997, Yokoyama et al. 
2004). The correlations between traditional CV risk factors such as lipids and 
IMT have been weaker and less consistent in diabetic patients than in the non-
diabetic population (Yamasaki et al. 1995, Temelkova-Kurktschiev et al. 1999, 
Mohan et al. 2000, Goff et al. 2000, Kong et al. 2000). Positive correlations 
have been demonstrated for Lp(a) (Yamamoto et al. 1997, Velmurugan et al. 
2003), LDL and HDL cholesterol (Goff et al. 2000), triglycerides (Temelkova-
Kurktschiev et al. 1999, Kong et al. 2000), total-to-HDL cholesterol ratio 
(Temelkova-Kurktschiev et al. 1999), non-HDL cholesterol (Elkeles et al. 
1996) and postprandial hypertriglyceridaemia (Teno et al. 2000). There are 
discrepancies in the literature as to which lipid parametres have been associated 
with IMT, although in most studies several parametres have been measured.
The progression of IMT is faster in diabetic than non-diabetic individuals 
(Wagenknecht et al. 2003). In a Canadian population-based cohort, IMT 
increased in a linear fashion with increasing HbA1c (Gerstein et al. 2003). 
Intensive antihyperglycaemic treatment slowed down intima-media thickening 
in type 1 diabetic patients over a six-year follow-up after the DCCT trial (Nathan 
et al. 2003). Interestingly, the length of time from diagnosis of type 2 diabetes 
to the initiation of insulin therapy has correlated positively with IMT in a cross-
sectional study (Zheng et al. 2003). Thiazolidinediones (Minamikawa et al. 
1998, Koshiyama et al. 2001) and metformin (Matsumoto et al. 2004) have been 
demonstrated to attenuate intima-media thickening in type 2 diabetic patients. 
Likewise some antihypertensive drugs have retarded the growth of IMT (Simon 
et al. 2002, Ludwig et al. 2002).
Carotid ultrasound scanning can be used to measure other aspects of carotid 
morphology beyond IMT, such as presence and character of plaques. Plaque 
evaluation has been used less frequently than IMT as a surrogate marker of CVD. 
Plaque morphology evaluation, as well as scanning protocols and determination 
of plaque burden vary greatly from study to study. Aortic and carotid plaques 
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predict cardiovascular mortality (Witteman et al 1986, Sakaguchi et al 2003). 
The number of plaques markedly contributed to the prognostic value of a 
predictive model for CVD and all-cause mortality, even though the model 
included major CVD risk factors such as age, medical and smoking histories, 
medication, lipoproteins etc. (Störk et al 2004). However, in hypertensive 
Japanese patients IMT was a better marker of end-organ damage than plaque 
score (Takiuchi et al 2004).
Calcifi cation of carotid plaques is inversely associated with clinical cerebrovascular 
symptoms compared with non-mineralised plaques (Kitamura et al 2004, 
Schaalan et al 2004), indicating that mineralisation is related to plaque stability. 
Furthermore, the extent of calcifi cation of the plaques correlates inversely with 
macrophage infi ltration of the plaque (Schaalan et al 2004). The power of carotid 
and femoral ultrasound scanning results for predicting cardiovascular mortality 
is greatly increased if presence, number and thickness of plaques is evaluated 
together with IMT (Griffi n et al 2002). Recently, carotid IMT, total plaque area 
and total plaque volume have been demonstrated to be determined by different 
cardiovascular risk factors. IMT correlated signifi cantly with hypertension, total 
plaque area with total cholesterol levels and smoking, and total plaque volume 
with diabetes (Al-Shali et al 2005).
2.8. Arterial stiffness and CVD and diabetes
High blood pressure is a major CVD risk factor. Blood pressure constitutes of 
mean blood pressure, which equals the steady component of blood pressure, 
plus the pulsatile component, pulse pressure (Safar et al. 2003). The normal 
compliance of the arterial tree helps to buffer the intermittent pressure changes 
caused by the left ventricular ejection of blood into the aorta (Wilkinson et al. 
2001). When the arterial elasticity diminishes, both the intra-arterial pressure 
and the speed of the pressure wave travelling along an artery (pulse wave velocity, 
PWV) increase (Woodman and Watts 2003).
Several techniques to investigate arterial stiffness have been established (Oliver 
and Webb 2003). The non-invasive methods can be divided in three main 
categories: measurements of 1) pulse wave velocity, 2) pulse pressure or blood 
fl ow waveform analysis, and 3) arterial distensibility and diameter (Woodman 
and Watts 2003). 
Arterial stiffening is the main cause of increasing systolic and pulse pressure 
after the age of 40 years (O´Rourke et al. 2002). Arterial stiffness is also an early 
phenomenon in diabetic vasculopathy, and has been proposed to independently 
predict CVD incidence (Woodman and Watts 2003). Moreover, it is strongly 
associated with atherosclerosis (van Popele et al. 2001), and it is an independent 
determinant of mortality in both diabetic and non-diabetic patients (Cruickshank 
et al. 2002, Nürnberger et al. 2002, Weber et al. 2004). 
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Arterial stiffness correlates with IMT in some (Taniwaki et al. 1999, Simons 
et al. 1999, Mackey et al. 2002, Ravikumar et al. 2002, Fukui et al. 2003) but 
not all (Oren et al. 2003, Zureik et al. 2002) studies. In the study by Zureik et 
al. (2002), carotid plaques were independently associated with arterial stiffness 
measured by pulse wave velocity (PWV), whereas the association between PWV 
and IMT disappeared after adjusting for age and blood pressure measurements. 
In that study, IMT was only measured from CCA, which may have affected the 
sensitivity of the IMT results. Fukui et al. (2003) found a positive correlation 
between augmentation and both IMT and plaque score using a more profound 
scanning protocol including CCA, CB, and ICA.
Arterial stiffness increases with the impairment of glucose tolerance (Henry et al. 
2003) and is higher in diabetic than non-diabetic subjects (van Dijk et al. 2003, 
Devereux et al. 2000, Brooks et al. 2001). Factors associated with increased 
stiffness in different studies have been glucose, insulin and triglycerides (Salomaa 
et al. 1995), insulin resistance and duration of diabetes (Emoto et al. 1998), age 
and HbA1c (Ravikumar et al 2002), age, systolic blood pressure, cholesterol and 
smoking  (Duprez et al. 2004, Fukui et al. 2002) and also male gender (Oren 
et al. 2003). 
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3. Aims of the Study
The aim of the study was to examine the role of new, non-traditional risk factors 
to explain the excess of vascular disease in type 2 diabetic subjects. In particular 
we aimed to ascertain if the CVD risk factors were similar in diabetic subjects 
with prevalent CVD compared with patients without clinical CVD.
The specifi c aims of the study were to
1)  investigate the role of the IGF system in relation to incipient atherosclerosis, 
traditional risk markers and the metabolic syndrome in type 2 diabetes (I)
2)  examine the connection between infl ammation and insulin resistance in type 2 
diabetes (II)
3) defi ne determinants of incipient atherosclerosis in type 2 diabetic and healthy 
subjects (III), and
4) examine correlates and interrelationships of intima-media thickness, plaque 
occurrence and mineralisation, and arterial stiffness (IV)
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4. Subjects and Study Design
We recruited the study subjects from among type 2 diabetic patients participating 
in the FIELD (Fenofi brate Intervention and Event Lowering in Diabetes) study 
of the Helsinki study site centre. The FIELD Study is a multinational randomised 
placebo-controlled double blind study that addresses the effect of fenofi brate in 
the prevention of cardiovascular morbidity and mortality in patients with type 
2 diabetes. It is a combined primary and secondary prevention trial including 
patients both with and without established cardiovascular disease. The study is 
being performed in Australia, New Zealand and Finland, and it is administered 
by the NHMRC Clinical Trials Centre, University of Sydney.  
A total of 9795 type 2 diabetic patients were recruited in the study globally 
(Keech A 2004). In Finland, 2068 patients were screened and 1393 recruited 
into the FIELD study. At the study site in Helsinki, study subjects were recruited 
by newspaper advertisements and from among several outpatient clinics in the 
capital area of Finland. The patients were randomly assigned to receive either 
placebo or micronised fenofi brate (200mg/d) for 5 years. Type 2 diabetic 
subjects between 50 and 75 years of age and serum total chol values between 1.0 
and 6.5 mmol/l with either serum triglycerides between 1.0 and 5.0 mmol/l or 
chol/HDL chol ratio over 4 were eligible. In Finland a more tight upper limit 
for total chol (5.5 – 6.0 mmol/l on screening visit) was followed due to local 
treatment practice. Subjects with hepatic or renal dysfunction, gallstones, lipid-
lowering medication, cyclosporin, alcohol overuse, or other severe mental or 
physical illness were excluded.
Two hundred and seventy patients were recruited in the FIELD main study 
in the Helsinki Centre.  Of these, 239 (76 female) participants volunteered 
for this substudy. The main reasons for not participating were: 1) The patient 
had already passed through the placebo run-in phase of the FIELD study and 
entered the blinded treatment phase, and was thus not eligible for this substudy, 
which started several months later than the main study, or 2) The patient’s 
daily schedule did not allow for the time needed for participating the substudy. 
Seventy-one substudy participants were diagnosed with previous CVD (defi ned 
as one or more of the following: angina pectoris, myocardial infarction, previous 
coronary artery bypass grafting (CABG) or percutaneous coronary intervention, 
stroke, TIA, carotid endarterectomy, claudication, leg amputation, peripheral 
arterial reconstruction or balloon dilatation as determined on the basis of clinical 
history and examination, including resting ECG, and review of all available 
patient records). 
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We recruited 93 healthy non-diabetic control subjects (44 female) by letters to 
the spouses of the study patients, by advertisements in the hospital magazine and 
intranet, and among retired pilots. The subjects had to be aged between 50-75 
years, with no signs or history of clinical CVD except for mild hypertension, 
and no other major chronic diseases. We performed a 75g oral glucose tolerance 
test to ensure normal glucose tolerance according to the WHO criteria. Subjects 
with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), 
total chol >6.0 mmol/l, LDL chol >4.0mmol/l, S-triglycerides >2.5 mmol/l, 
transaminase levels over 2 x upper limit normal, or abnormal thyroid stimulating 
hormone (TSH) concentration were not eligible.
All patients and control subjects signed informed consent forms.  The Ethics 
Committee of the Helsinki University Central Hospital approved the protocol. 
In addition we acquired approval by the Ethics committees of Helsinki City 
health care, Vantaa City health care, Peijas hospital, and Jorvi hospital, as we also 
recruited patients from these sites.
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5. Methods
5.1.  Laboratory analyses
All laboratory analyses were performed during the placebo run-in period of the 
FIELD Study, before fenofi brate intervention. Blood samples were obtained 
the morning after an overnight fast from both patients and control subjects. 
Coeffi cients of inter-assay variation (CV) are presented as per cent after each 
method, if available.
5.1.1. Glucose, insulin, and C-peptide measurements
We performed a 75 g oral glucose tolerance test on healthy control subjects to 
ensure normal glucose tolerance according to WHO criteria (WHO 1999). 
Blood samples were drawn at 0, 30, 60 and 120 minutes for the determination of 
P-glucose, S-insulin and c-peptide. For diabetic patients, we only measured fasting 
levels of glucose, insulin, and c-peptide. Fasting and post-load plasma glucose was 
measured by the hexokinase method (Roche Diagnostic Gluco-quant) using either 
a Hitachi 917 or a Modular analyser (Hitachi Ltd, Tokyo, Japan). We measured 
HbA1c by nefelometric inhibition of agglutination (CV 2.6 %) using a DCA 
2000 analyser (Bayer Ames Technicon, USA).  Serum insulin concentrations were 
determined by double-antibody RIA (Pharmacia RIA kit, Pharmacia, Uppsala, 
Sweden, CV 6.5 %) after precipitation with polyethylene glycol. C-peptide was 
determined by RIA (RIA-coat®C-peptid, Byk-Sangtec Diagnostica, Dietzenbach, 
Germany, CV 10 %).
5.1.2. Lipid and lipoprotein measurements
Total chol (CV 2 %) and triglyceride (CV 2 %) levels were measured in serum by 
automated enzymatic procedures (Hoffman-La Roche, Basel, Switzerland). LDL 
and HDL chol were determined after separating the lipoprotein fractions from 
fresh fasting sera by sequential ultracentrifugation (Taskinen et al. 1988). Serum 
HDL chol was additionally quantifi ed by the phosphotungastic acid/magnesium 
chloride precipitation procedure (Hoffman-La Roche, Basel, Switzerland, 
CV 2.8 %). In Study IV, we calculated LDL chol using the formula of Friedewald. 
Apo B was measured by an immunochemical assay from Orion Diagnostica 
(Espoo, Finland, CV 4 %). Lp(a) was measured by turbidimetric immunoassay 
(Wako Chemicals GmbH, Neuss, Germany). 
We measured LDL peak particle diameters (LDL size) from serum samples that 
had been stored at -80°C using nondenaturing linear gradient gel electrophoresis, 
as previously described in detail (Vakkilainen et al. 2002), (CV 1.2 %). 
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5.1.3. Cytokines, other infl ammatory markers, and endothelial 
activation molecules
Circulating ICAM-1, VCAM-1, E-selectin l, ultra-sensitive CRP, SAA, IL-6, 
M-CSF and sPLA2 concentrations were determined by commercially available 
ELISA; the ICAM-1 (CV 7.4%), VCAM-1 (CV 9.2 %), E-selectin (CV 7.3 %), 
IL-6 (CV 15.1 %) and M-CSF kit (CV 5.8 %) by R&D Systems, MN, USA; the 
ultra-sensitive CRP kit (CV 12.8 %) by Medix Biochemica, Kauniainen, Finland; 
the SAA kit (CV 21.9 %) by Biosource International, Camarillo, CA, USA; and 
the sPLA2 kit (CV 22.1 %) by Cayman Chemical Company, Ann Arbor, USA).
5.1.4. Albumin excretion rate 
Urinary albumin excretion rate (UAER) was measured from three sequential 
overnight urinary collections. The median of the three collections was used to 
determine normoalbuminuria (< 20 ug/min), microalbuminuria (20-200 ug/min) 
or macroalbuminuria (> 200 ug/min). Interassay repeatability: CV 2.8% at 
concentration of albumin 191 mg/l, 2.0 % at 96.5 mg/l, and 3.5 % at 18.0 mg/l. 
Intra-assay repeatability: CV 4.2 %.
5.1.5. The IGF system
IGF-I was determined from the serum samples using the DSL-10-5600 
ACTIVETM IGF-I Enzyme-Linked Immuno-Sorbent Assay Kit (CV 8 % at the 
levels of 135.6 ng/ml). The assay uses a modifi ed version of the standard acid-
ethanol extraction procedure. 
IGFBP-1 concentration was determined by a two-site immunofl uorometric assay 
as described earlier (Koistinen et al. 1996) using two monoclonal antibodies, 
F34-15C9 and F36-9G3 (CV 7.5 % at the level of 54 ng/ml).  
IGFBP-3 was determined from serum samples using monoclonal antibodies 
(mAb) generated against recombinant IGFBP-3E.Coli  (Koistinen et al. 1994) 
(CV 8 % and 3.7 % at the levels of 98 ng/ml and 18.8 ng/ml, respectively). The 
assay uses mAb F42-1B6 as the solid phase antibody and mAb F41-5C11 as 
the Eu-labeled tracer. The assay had no cross-reactions with the other human 
IGFBPs or IGFs.
5.2. The homeostasis model (HOMA)
To assess insulin resistance the homeostasis model (HOMA IR) was calculated 
by (fasting insulin (mU/l) x fasting glucose (mmol/l))/22.5 (Matthews et al. 
1985, Haffner et al. 1997, Radziuk 2000).  
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5.3.  B-mode ultrasonography of the carotid arteries
5.3.1. Intima-media thickness (IMT)
All ultrasound scans were performed with a Hewlett Packard Image Point 
M2410A ultrasound system and a high frequency 10 MHz linear array transducer. 
Relevant parts of the scanning procedures were videotaped with a Panasonic 
AG-MD830E PAL S-VHS VCR. Both carotid arteries were scanned with the 
patient being in the supine position with her/his head rotated 45 degrees away 
(if possible) from the side being scanned. 
Longitudinal images were displayed from three projections - the anterolateral, the 
lateral and the posterolateral - for the common carotid artery (CCA), the carotid 
bulb (CB) and the internal carotid artery (ICA). The arterial segments assessed 
were 1) the distal 1 cm of CCA, 2) the entire carotid bulb, and 3) the proximal 1 
cm of ICA (Figure 3). Scanning was focused and measurements taken of a total 
of 28 sites per patient of both the right and the left carotid arteries from three 
projections for both the far wall (FW) and the near wall (NW) of the CCA and 
CB, and the one best visualized projection for ICA (Fig. 3). The images were 
frozen in the diastole, assessed as the phase when the lumen diameter is at it’s 
narrowest and IMT at it’s largest. Relevant parts of the scanning were recorded. 
All scans were performed in Helsinki.
Figure 3. Carotid artery scan
ICA, internal carotid artery. CB, carotid bulb. CCA, common carotid artery. 
NW, near wall. FW, far wall
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Figure 4. IMT imaging sites and projections (modifi ed after Ylitalo 2001 and 
Soro-Paavonen 2004)
- CCA and CB: anterolateral, anterior and posterior projections bilaterally
- ICA: single best projection bilaterally
- All projections: both near wall and far wall IMT
- A local thickening (plaque) visible in CB FW
 
Computer analysis of the ultrasound images was performed using a PC with 
a video frame grabber interfaced to a PAL S-VHS VCR, at Oy Jurilab Ltd 
(www.jurilab.com) in Kuopio. The Prosound software, developed by Robert 
Selzer (Caltech, Pasadena, CA, USA), was used for the analysis of ultrasound 
images to measure IMT (Selzer et al. 1994). This software digitises the video 
ultrasound image, locates the interfaces, and computes the IMTs. The Prosound 
software enables 100 measurements per 1 cm edge length. IMT is determined 
as the mean difference at on the average 100 points between intima/lumen 
and media/adventitia interface. The following variables were derived: the mean 
IMT, the maximal IMT, and the minimal IMT. All outcome variables were fi rst 
calculated for each subject. 
As the primary outcome variable for each subject we chose the mean of 
maximal IMT (Max IMT) measurements over all 28 scanned carotid sites, as it 
corresponds to IMT over the carotid artery from CCA through the carotid bulb 
to the initial 1 cm of ICA.  Secondary outcome variables were 1) the mean of 
mean IMTs (Mean IMT) over all scanned carotid sites, 2) the mean of mean far 
wall IMT over all scanned carotid far wall sites (FW), 3) the mean of maximum 
over all scanned CCA sites, 4) the mean of maximum over all scanned CB sites, 
5) the mean of the maximum for all scanned ICA sites, and 6) the plaque height 
difference between site-specifi c maximums and minimums averaged for all 
scanned carotid sites (CarDif). 
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The ultrasound examination was carried out for 236 of the 239 diabetic study 
patients and all of the 93 non-diabetic control subjects. One diabetic subject 
could not be scanned due to neck arthrodesis and two due to impaired visibility 
of the carotid arteries.  The IMT scans of the patients were all read by one 
ultrasound technician, Arja Malkki. Reading of the scans of the healthy controls 
was divided between two readers, Arja Malkki and Jarmo Tiikkainen. All readings 
were performed in Kuopio.
5.3.2. Scoring of plaques
Jarmo Tiikkainen reread 99 videotapes, which were randomly taken from the 
whole material, according to a different protocol for the determination of local 
thickenings (plaques) to assess the degree of atherosclerosis. The local changes 
at every site (bilateral FW and NW of three projections in CCA and CB, FW 
and NW of the best visualised projection in ICA) were divided into two main 
categories, soft change and mineralised plaques and graded as follows: 
1. Soft change
 0 = no change
 1 = thickening of artery wall 
  (IMT ≥ 1.5mm at CCA and/or ≥ 2mm at CB or ICA)
 2 = protrusion of 25 – 39 per cent of the lumen diameter
 3 = protrusion over 40 per cent of the lumen diameter
2. Mineralisation
 0 = no mineralisation
 1 = solitary mineralisation
 2 = several mineralisations or a cluster of mineralisations
For statistical analysis, the results of every single patient of this second ultrasound 
grading were further categorised so that the “worst” grading of all assessed sites 
for soft and mineralised changes was chosen to represent the level of soft and 
mineralised changes for that patient.
Eeva Leinonen (E.L.) performed the carotid scans of all patients and control 
subjects. E.L. scanned 11 study subjects twice each with one week’s interval 
between measurements to assess the repeatability of the scans. The intra-observer 
repeatability (R) for Max IMT was 0.994 with a standard error of measurement 
errors (SE) 0.0152.  The reader Arja Malkki’s repeatability was assessed earlier in 
another study with an identical carotid ultrasound protocol (Ylitalo et al. 2002). 
The intra-reader R for Max IMT for Arja Malkki was 0.996 and SE 0.0082. Arja 
Malkki and Jarmo Tiikkainen read 10 scans independently from each other to 
assess inter-reader repeatability. The inter-reader R for Max IMT was 0.977 and 
SE 0.032.
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5.4. Pulse wave analysis (PWA)
When the arterial pressure wave generated in systole travels throughout the 
arteries, at different points of discontinuity the pressure wave is refl ected back, 
generating a backward travelling refl ected wave (Nichols and Singh 2002, Safar 
et al. 2003). The amplitude and shape of the actual pressure wave is composed by 
the intensity of these two wave components and the timing between them (Safar 
et al. 2003). As arterial stiffness increases, the velocity of both waves increases, 
therefore the refl ected wave arrives earlier in the central aorta and augments the 
arterial pressure during late systole, causing an increase in ventricular afterload 
(O’Rourke and Mancia.1999). The augmentation of the central pressure divided 
by the pulse pressure is defi ned as the augmentation index (AIx), and is a measure 
of arterial stiffness (Avolio et al. 1985, Kelly et al. 1989, Wilkinson et al. 2001). 
We used the technique of pulse wave analysis (PWA) to determine central aortic 
pressure, augmentation, and the AIx (O´Rourke and Gallagher 1996, Wilkinson 
et al. 1998, Westerbacka et al. 1999). Pressure waves are recorded by applanation 
tonometry from the radial artery. A validated and generalised transfer function 
(Wilkinson et al. 1998) is then used to generate the corresponding central 
arterial waveform. The aortic waveform in pulse wave analysis is subject to further 
analysis for the calculation of aortic pressure augmentation, the AIx, central 
blood pressure and ejection duration (duration of systolic period in milliseconds), 
and Buckberg’s subendocardial viability ratio (SEVR, area of diastole divided 
by area of systole during one cardiac cycle in the aorta). The measurement of 
augmentation index is highly reproducible (Wilkinson et al. 1998).
A sole investigator (Jukka Westerbacka) performed all measurements from the 
radial artery by applanation tonometry using a Millar tonometer (SPC-301; 
Millar Instruments, Houston, TX). 
Data were collected directly into a desktop computer and processed with 
SphygmoCor Blood Pressure Analysis System (BPAS-1; PWV Medical, Sydney, 
Australia), which allows continuous on-line recording of the radial artery 
pressure waveform. We used the integral system software to calculate an average 
radial artery waveform, and to generate the corresponding ascending aortic 
pressure waveform using a previously validated transfer factor (Pauca et al. 2001, 
Karamanoglu et al. 1993). 
We measured blood pressure with a calibrated mercury sphygmomanometer 
after the subject had rested in the supine position for 10 minutes. The average of 
three measurements was used for analysis. 
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5.5. Anthropometric variables
We measured waist circumference (midway between lowest rib and iliac crest) 
and hip circumference (maximum of buttocks) to the centimetre. Body mass 
index (BMI) was calculated by dividing weight in kilograms by height in meters 
squared (kg/m2). We used the waist circumference and the waist-to-hip ratio 
(WHR) as measures of body fat distribution.
5.6.  Statistical methods
Parametres with skewed distributions (including HOMA IR) were log10-
transformed for statistical analysis. Due to signifi cant differences in the age and 
gender distribution between diabetic patients and healthy controls, all analyses 
to compare patients and healthy controls were adjusted for age and gender. 
Pearson and partial Pearson correlation coeffi cients were used to demonstrate 
relationships between variables. 
Differences between patients without and with CVD and healthy controls were 
examined by One-Way ANOVA for normally distributed continuous data, by 
the Kruskal Wallis H -test or the Mann Whitney U -test for continuous data not 
normally distributed, and by the Chi squared test for categorical variables. We used 
the GLM Univariate analysis in Study II to compare biochemical characteristics in 
HOMA IR quartiles, to calculate differences between IMT measures in diabetic 
and healthy subjects in Study III, to calculate differences between augmentation 
and AIx in diabetic subjects with or without CVD adjusting for confounders, 
and to calculate differences between infl ammatory and endothelial markers in 
diabetic and control subjects adjusting for confounders. Dunnett s´ two-sided 
post hoc test was used in Studies II and III and Bonferroni’s test in Study IV to 
calculate signifi cant differences between subgroups. Differences between genders 
in Study IV were calculated using the Student’s T-test.
Biochemical characteristics in HOMA IR quartiles (Study II) and Max IMT 
tertiles (Study III) were compared by One-Way ANOVA using Dunnett s´ two-
sided post hoc test.
In Study I, we used linear regression analysis for the whole study cohort and 
for subgroups to explain variation in Max IMT. To adjust for confounders, we 
entered these parameters in the regression analyses in step one. Parameters with 
even a weak correlation (r >0.200) with Max IMT, but independent from each 
other, were entered in step 2. Parameters were removed until the best fi tting 
model was achieved. Similarly, we used linear regression analysis to investigate 
determinants of HOMA IR and BMI in Study II, determinants of IMT in the 
healthy controls in Study III, and determinants of PWA and IMT in Study IV.
In Study III, we used factor analysis to defi ne the main entities determining IMT 
in the diabetic patients. Only factors with eigenvalues over 1.0 were retained. 
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Varimax rotation was then performed to achieve factors without intercorrelations. 
We considered variables with loadings outwith the –0.40 to 0.40 range on a 
factor to be its major constituents.  The factor scores were calculated by the 
regression method and saved as variables to be used in correlation analyses and 
linear regression analysis to investigate determinants of IMT.
We used the GraphPad Prism version 3.00 for Windows (GraphPad Software, 
San Diego, CA, www.graphpad.com) when comparing linear regression slopes 
to study the effect of age on IMT in Study 2. All other statistical analyses were 
performed with versions 9.0, 10.0 or 11.0 of the SPSS for Windows software 
(SPSS Inc., Chigaco, USA). A p-value of < 0.05 was considered signifi cant in all 
analyses.
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6. Results
6.1. Study population  
The characteristics of our study subjects are presented in Tables 4 and 5.  There 
was a marked preponderance of males among our diabetic cohort, whereas among 
the controls the gender distribution was almost equal. The control subjects were 
younger than the patients, and, as expected, also had a signifi cantly lower waist 
circumference and BMI. Despite the different lipid inclusion criteria for diabetic 
and control subjects, the mean values for total and LDL chol were comparable. 
Diabetic patients had lower HDL chol and higher levels of TG, Apo B, and Lp(a) 
than control subjects, consistent with diabetic dyslipidaemia. The respective 
modes of diabetes treatments as expressed by the number of participants and 
(percentage) were: diet-only in 34 (14%), oral antihyperglycaemic agents (OHA) 
in 149 (62%), insulin only in 11 (5%), and a combination of OHA and insulin in 
45 (19%) for the diabetic patients group. 
Among the diabetic group, 184 (77%) patients had the metabolic syndrome 
according to the NCEP criteria. In the 77 diabetic patients with clinical CVD, 
the metabolic syndrome was prevalent in 56 (79%) patients, and in the 168 
diabetic patients without CVD the metabolic syndrome occurred in 128 (76 %) 
patients.  Data was suffi cient to calculate the presence of the metabolic syndrome 
in 83 of the 93 control subjects, seven (8%) of whom had the metabolic syndrome 
as defi ned by NCEP guidelines. 
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Table 4. Subject characteristics.
DM with 
CVD
N = 71
DM without 
CVD
N = 168
Controls
N = 93 Difference (p)
Mean     SD Mean     SD Mean    SD
Controls
vs. 
patients
Patients
without 
vs. with 
CVD
Age (years) 63.2  6.5 60.8 6.5 58.8 6.4 0.001 = 0.015
Gender (N male/female) 51 / 20 110 / 58 49/ 44 = 0.016 < 0.001
BMI (kg/m2) 31.0 5.6 30.4 5.4 25.4 2.8 < 0.001 ns
Waist (cm) 104.1 14.7 101.2 12.5 86.2 11.2 < 0.001 ns
WHR 0.94 0.07 0.93 0.07 0.84 0.09 < 0.001 ns
DM duration (years) 8.7 6.8 7.3 6.1 - - - ns
Pulse pressure (mmHg) 60 17 56 14 52 14 = 0.007 ns
Systolic blood pressure 
(mmHg)
146 18 144 17 134 16 < 0.001 ns
Diastolic blood pressure 
(mmHg)
86 10 88 11 82 8 < 0.001 ns
Total chol (mmol/l) 5.1 0.7 5.0 0.7 5.0 0.8 ns ns
HDL chol (mmol/l) 1.1 0.3 1.2 0.4 1.5 0.4 < 0.001 ns
LDL chol (mmol/l) 3.3 0.6 3.1 0.6 3.0 0.6 ns ns
Triglycerides (mmol/l) 1.8 0.8 1.8 0.8 1.0 0.3 < 0.001 ns
Apo B (mg/dl) 101  23 104 25 91 17 ns ns
Lp(a) (mg/dl) 168 138 148 141 144 109 ns ns
fP-glucose (mmol/l) 8.0 1.7 7.9 2.3 5.4 0.5 < 0.001 ns
HbA1c (%) 7.5 1.4 7.3 1.3 5.1 0.3 < 0.001 ns
C-peptide (nmol/l) 1.2 1.1 1.0 0.8 0.6 0.3 < 0.001 ns
Insulin (mU/l)* 14.2 6.7 13.3 9.3 6.5 2.3 < 0.001 ns
IGF-I (nmol/l) 149.8 62.1 142.2 64.0 163.3 54.5 = 0.001 ns
IGFBP-1 (μg/l) 87.2 70.8 85.4 74.6 108.5 57.9 < 0.001 ns
IGFBP-3 (μg/l) 4719 1558 4462 1623 5643 1652 < 0.001 ns
Smoking 
(N, never/ex/current)
28/37/6 71/69/28 52/33/7** = 0.03 ns
 
* Diabetic patients with insulin treatment excluded.
** Data missing from 1 subject.
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Table 5. Prevalent medications and cardiovascular diseases
DM with 
CVD
N = 71
DM without 
CVD
N = 168
Controls
N = 93
Angina pectoris 37 (52%) - -
Myocardial infarction 6 (9%) - -
CABG 10 (14%) - -
Coronary angioplasty 6 (9%) - -
Stroke 13 (18%) - -
TIA 7 (10%) - -
Claudication 23 (32%) - -
Peripheral revascularisation 5 (7%) - -
Any oral antihyperglycaemic agent 
(OHA)
63 (89%) 134 (80%) -
Sulphonylurea 43 (61%) 95 (57%) -
Metformin 47 (66%) 99 (59%) -
Other OHA (guargum, acarbose, 
glinides)
4 (6%) 8 (5%) -
Insulin treatment 23 (32%) 34 (20%) -
Combination of OHA and insulin 21 (17%) 25 (15%) -
Any medication for hypertension 36 (51%) 75 (45%) 16 (17%)
β-blockers 34 (48%) 23 (14%) 8 (9%)
ACE inhibitors 20 (28%) 49 (29%) 3 (3%)
AII inhibitors 2 (3%) 7 (4%) 6 (6%)
Ca channel blockers 19 (27%) 33 (20%) 8 (9%)
ASA 47 (66%) 106 (63%) 13 (14%)
Nitrates 12 (17%) 2 (1%) -
 
6.2.  The IGF system and atherosclerosis 
(Study I and unpublished data)
6.2.1. The IGF system, age, anthropometric measurements and 
insulin resistance
The concentrations of IGF-I, IGFBP-1 and IGFBP-3 were all higher in the 
healthy controls than in the diabetic patients (Table 4). However, within the 
diabetic group they were consistently lower regardless of the presence of clinical 
CVD. In the diabetic patients, the IGFBP-1 concentration increased with age 
(r = 0.217, p < 0.001) and correlated inversely with BMI (r = -0.386, p < 0.001), 
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waist circumference (r = -0.438, p < 0.001), and waist-to-hip ratio (r = -0.371, 
p < 0.001), whereas IGF-I and IGFBP-3 did not correlate with these parameters. 
As expected, there was a strong inverse relationship between the concentrations 
of insulin and IGFBP-1 both in the diabetic patients (r = -0.461, p < 0.001) and 
in the healthy controls (r = -0.434, p < 0.001).
In the diabetic subjects, the concentration of IGFBP-1 decreased steadily with 
increasing prevalence of the components of the metabolic syndrome as defi ned by 
the NCEP defi nition (Expert panel 2001); from a mean of 144 μg/l in patients 
with only diabetes to 54 mg/l in patients with all fi ve components (p < 0.001). 
This inverse relationship between IGFBP-1 and the metabolic syndrome was 
more consistent than the correlation between concentration of insulin and the 
metabolic syndrome (Fig. 5), although the relationship between insulin levels 
and degree of the metabolic syndrome also was highly signifi cant (p < 0.001).  
Figure 5. Mean concentrations of IGFBP-1 and insulin in categories of diabetic 
patients having a different number of components of the metabolic syndrome.
    
We also calculated HOMA IR for the diabetic subjects without insulin treatment 
(N = 182). There was a strong inverse relationship between IGFBP-1 and HOMA 
IR  (r = -0.437, p < 0.001). This inverse correlation remained highly signifi cant 
even after adjusting for age, gender, BMI, and diabetes duration (r = -0.304, 
p < 0.001).
In the healthy controls, the concentrations of IGFBP-1, IGF-I, and IGFBP-3 
were not related to age. Similar to that found in the diabetic patients, there 
was a signifi cant inverse correlation between IGFBP-1 and BMI (r = -0.325, 
p = 0.005), waist circumference (r = -0.374, p < 0.001), waist-to-hip ratio 
(r = -0.326, p = 0.005), and HOMA IR (r = -0.465, p < 0.001). The inverse 
relationship between IGFBP-1 and HOMA IR was also signifi cant in the healthy 
subjects after adjusting for age, gender, and BMI (r = -0.457, p < 0.001).
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There was an inverse relationship between levels of C-peptide and IGFBP-1 in 
both diabetic subjects (r = -0.415, p < 0.001) and healthy controls (r = -0.401, 
p = 0.038) in partial correlation analysis adjusting for age, gender, BMI and, for 
the diabetic subjects, duration of diabetes.
6.2.2 The IGF system and other CVD risk factors
After correcting for age, BMI, gender, and diabetes duration, we found signifi cant 
positive correlations between IGFBP-3 and total chol (r = 0.254, p = 0.013), 
LDL -chol (r = 0.292, p = 0.004), Apo B (r = 0.234, p = 0.022), and Lp(a) 
(r = 0.235, p = 0.021). There were also similar correlations between IGF-I and 
LDL chol (r = 0.226, p = 0.027) and Lp(a) (r = 0.204, p = 0.047). Other 
correlations were not signifi cant (Study I). These correlations were not present 
in the healthy control subjects (data not shown). 
6.3. Insulin resistance and infl ammation 
(Studies II and III)
The concentrations of acute phase reactants, cytokines and cellular adhesion 
molecules were generally higher in diabetic patients than in the healthy 
control group (Table 6). After adjusting for age, gender, BMI and smoking, 
the differences between diabetic and control subjects remained signifi cant for 
CRP (p = 0.019), M-CSF (p < 0.001), E-selectin, (p = 0.025), and ICAM-1 
(p < 0.001).
Table 6. Infl ammatory and endothelial markers in diabetic and healthy subjects
 
Diabetic subjects
Median, range
Controls
Median, range
DM vs. 
controls
Difference (p)
CRP mg/l 1.7 0.1 - 38 0.9 0.2 - 17 < 0.001
hSAA ug/ml 23 4.8 - 2082 20 5.1 - 153 = 0.006
IL-6 pg/ml 2.4 0.5 - 1687 2.0 0.5 - 25 = 0.008
M-CSF pg/ml 450 128 - 1694 305 71 - 1859 < 0.001
sPLA2 ng/ml 3.1 < 0.01 - 25 2.2 0.6 - 8.2 = 0.002
E-selectin ng/ml 56 15 - 455 45 12 - 110 < 0.001
ICAM-1 ng/ml 259 53 - 549 220 88 - 380 < 0.001
VCAM-1 ng/ml 556 233 - 1400 527 306 - 850 = 0.053
 
 
We calculated the correlations between the infl ammatory markers and HOMA 
IR and between the endothelial markers and HOMA IR in the diabetic subjects 
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without insulin treatment.  Adjustments were made for age, gender, and smoking 
(Table 7). HOMA IR correlated signifi cantly with all of the markers in the diabetic 
subjects, but with only CRP and E-selectin in the healthy controls. When these 
correlations were further adjusted for BMI, the correlation remained signifi cant 
for all markers in diabetic subjects: CRP (p = 0.013), hSAA (p = 0.046), IL-6 
(p = 0.008), M-CSF (p = 0.023), sPLA2 (p = 0.025), E-selectin (p < 0.001), 
ICAM-1 (p = 0.001), and VCAM-1 (p = 0.01). In the control group, only 
E-selectin remained signifi cantly correlated (p = 0.05) with HOMA after 
adjusting for age, gender, smoking, and BMI.
 
Table 7. Correlation between infl ammatory and endothelial markers with 
HOMA IR adjusted for age, gender and smoking.
Diabetic patients Control subjects
r p r p
CRP mg/l 0.324 < 0.001 0.275 = 0.009
hSAA ug/ml 0.237 = 0.002 0.165 ns
IL-6 pg/ml 0.316 < 0.001 0.142 ns
M-CSF pg/ml 0.180 = 0.018 0.127 ns
sPLA2 ng/ml 0.236 = 0.002 0.136 ns
E-selectin ng/ml 0.349 < 0.001 0.337 = 0.002
ICAM-1 ng/ml 0.329 < 0.001 0.055 ns
VCAM-1 ng/ml 0.212 = 0.005 0.137 ns
After adjusting for age, gender and smoking, HOMA IR correlated signifi cantly 
and positively with BMI, waist-to-hip ratio and waist circumference in diabetic 
subjects (Study III) and with BMI and waist circumference in the control group 
(unpublished). The partial correlation coeffi cients for diabetic and healthy 
individuals, respectively, were for BMI: r = 0.388, p < 0.001, and r = 0.389, 
p < 0.001; WHR: r = 0.211, p = 0.016, and r = 0.265, p = 0.062; and waist 
circumference: r = 0.457, p < 0.001, and r = 0.358, p = 0.002.
Partial correlation coeffi cients between infl ammatory and endothelial markers 
and waist circumference, adjusted for age, gender, and smoking, are presented in 
Table 8. Similar to the association between HOMA IR and these markers, only 
CRP and E-selectin correlated with waist circumference in the healthy group, 
whereas in the diabetic group the correlation between low-grade infl ammation and 
endothelial activation and waist circumference was signifi cant and constant.
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Table 8. Correlation between infl ammatory and endothelial markers with waist 
circumference adjusted for age, gender and smoking.
Diabetic patients Control subjects
r p r p
CRP mg/l 0.374 <  0.001 0.308 = 0.009
hSAA ug/ml 0.231 < 0.001 0.027 ns
IL-6 pg/ml 0.415 < 0.001 0.059 ns
M-CSF pg/ml 0.134 = 0.043 0.003 ns
sPLA2 ng/ml 0.185 = 0.005 0.003 ns
E-selectin ng/ml 0.314 < 0.001 0.303 < 0.01
ICAM-1 ng/ml 0.230 < 0.001 -0.081 ns
VCAM-1 ng/ml 0.131 = 0.048 0.178 ns
Glycaemic control of the diabetic patients, assessed by HbA1c, was signifi cantly 
and positively related to CRP, hSAA, ICAM-1 and E-selectin (Study III). In 
addition, in diabetic subjects HbA1c correlated signifi cantly and independently 
of age, gender, and BMI, with HOMA IR, CRP, hSAA, and E-selectin (Study 
III). No consistent relationship existed between HbA1c and infl ammatory or 
endothelial activation variables in the control group.
6.4. Determinants of intima-media thickness IMT 
(Studies I, III, IV, and unpublished data)
Table 9 shows the carotid IMT results for diabetic patients and healthy controls. 
All IMT parametres were signifi cantly greater in diabetic than healthy subjects. 
Furthermore, most of the IMT parameters were greater in diabetic patients with 
CVD than in patients without CVD. Nevertheless, the differences between IMT 
measurements in diabetic patients with and without CVD disappeared after 
adjusting for age, gender and smoking (Study III).
Diabetic men had higher values than diabetic women for Max IMT (1.35 vs. 
1.24 mm, p = 0.031), mean IMT (1.07 vs. 1.02 mm, p = 0.027), FW IMT (1.07 
vs. 1.02 mm, p = 0.049), CB IMT (1.54 vs. 1.45 mm, p = 0.05), and ICA IMT 
(1.27 vs. 1.13 mm, p = 0.004). In the healthy controls, there was no gender 
difference in any of the IMT variables. Unexpectedly, smoking was not related to 
any of the IMT parameters in either diabetic patients or healthy controls (data not 
shown). The duration of diabetes correlated with Max IMT in diabetic subjects 
with CVD, but duration did not correlate with IMT either among the diabetic 
subjects without CVD (Study I) or in the total diabetic cohort (Study IV).
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Table 9. IMT in healthy and diabetic subjects
DM with 
CVD N = 71
DM without 
CVD N = 168
Controls 
N = 93
Difference (p)
IMT 
parametres 
Mean 
(mm)
SD Mean 
(mm)
SD Mean 
(mm)
SD Controls 
vs. 
patients
Patients 
without vs. 
with CVD
Max IMT 1.39 0.22 1.31 0.24 1.19 0.22 < 0.001 = 0.006
Mean IMT 1.09 0.19 1.03 0.17 0.93 0.18 < 0.001 = 0.005
FW IMT 1.11 0.23 1.03 0.20 0.93 0.19 < 0.001 = 0.007
CCA IMT 1.25 0.18 1.17 0.19 1.06 0.17 < 0.001 < 0.001
CB IMT 1.56 0.35 1.49 0.33 1.36 0.32 < 0.001 = 0.111
ICA IMT 1.30 0.45 1.20 0.38 1.10 0.28 = 0.006 = 0.075
CarDif 0.59 0.11 0.56 0.12 0.52 0.11 = 0.001 = 0.046
In Study I, we performed linear regression analysis to explain variation of 
MaxIMT in the entire diabetic cohort controlling for age, gender, BMI, presence 
or absence of OHA or insulin medication, and diabetes duration. The main 
determinants of Max IMT were age, IGFBP-1, pulse pressure, and Lp(a) (Study 
I). In addition, diabetes duration and insulin treatment remained in the model. 
The model explained 28.3 % of variation of Max IMT.  
When we investigated the blood pressure and compliance effects on  MaxIMT, 
adjusting only for gender and age, the only correlates to MaxIMT were nU-
albumin, augmentation and AIx (Study IV).
The presence of the metabolic syndrome, or number of the components of the 
metabolic syndrome were not correlated with IMT or with the presence of CVD 
either the diabetic or the healthy subgroup (data not shown). Most of the diabetic 
subjects had metabolic syndrome (N = 184 (77%); data was missing for one 
subject). In contrast only seven of the healthy control subjects had the metabolic 
syndrome, therefore the study probably was not suffi ciently statistically powered 
to detect any difference in IMT parametres between subjects with and without 
metabolic syndrome.
In Study III, we included the acute phase reactants, cytokines and endothelial 
activation markers in the analyses to examine determinants of IMT. In Study III 
we did not include the IGF system parametres, which we had examined in Study 
I.  We chose to perform factor analysis due to the vast number of parametres each 
of which can have several intercorrelations.  Factor analysis yields independent 
factors, which correspond to entities implicated in IMT thickening. 
Factor analysis produced biologically meaningful factors only in the diabetic 
group but not in the healthy control group. The eight factors derived in the 
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diabetic cohort were named after the parameters with a high loading for 
each factor (Table 10): 1) “obesity factor” (high loading of BMI, waist, hip 
circumference) 2) “dyslipidaemic factor” (triglycerides, LDL size, Apo B, inversely 
HDL cholesterol), 3) “cholesterol factor” (total and LDL cholesterol, Apo B), 
4) “endothelial factor” (M-CSF, E-selectin, ICAM-1, VCAM-1), 5) “blood 
pressure factor” (systolic blood pressure and pulse pressure), 6) “infl ammation 
factor” (CRP, hSAA, IL-6, sPLA2), 7) “duration factor” (age, DM duration), 
and 8) “glucose factor” (glucose, HbA1c). 
Table 10. Factor scores derived by factor analysis: diabetic patients.
Rotated Component Matrix (a)
 Variable Components, named according to variables with high loading
1 
Obesity
2 
Dyslipi-
daemia
3 
Chole-
sterol
4 
Endo-
thelial
5 
Blood 
pressure
6 
Infl am-
mation
7 
Dura-
tion
8 
Glucose
Age -0.03 -0.04 0.03 0.22 0.27 0.04 0.70 0.07
DM duration 0.09 -0.13 -0.08 -0.08 0.14 -0.12 0.65 0.24
BMI 0.91 0.00 0.03 0.06 0.07 0.20 -0.06 -0.02
Waist 0.92 0.17 -0.08 0.09 -0.06 0.06 -0.06 -0.02
Hip 0.92 -0.02 0.05 0.11 0.04 0.22 0.06 0.02
Smoking 0.08 0.13 -0.20 -0.22 -0.22 0.03 -0.15 -0.35
Diastolic BP 0.17 0.02 0.13 0.09 0.38 -0.09 -0.72 0.17
Systolic BP 0.07 -0.01 0.06 0.05 0.97 0.00 -0.11 0.10
Pulse pressure -0.02 -0.03 -0.01 0.00 0.89 0.06 0.30 0.02
Glucose -0.06 0.07 -0.05 0.04 0.01 0.03 0.01 0.81
HbA1c 0.06 0.12 -0.03 0.07 0.05 0.11 0.01 0.79
CRP 0.30 0.03 -0.07 0.06 -0.00 0.76 -0.15 0.13
HSAA 0.13 -0.04 -0.02 -0.03 -0.10 0.80 -0.01 0.17
IL-6 0.34 0.09 -0.27 0.38 0.10 0.44 0.05 -0.10
M-CSF -0.01 0.15 -0.10 0.69 0.07 0.09 0.01 0.01
sPLA2 0.05 0.01  -0.00 0.27 0.15 0.65 0.11 -0.12
E-selectin 0.23 0.22  0.00 0.44 -0.02 0.09 -0.21 0.23
ICAM-1 0.14 -0.07 -0.04 0.65 0.12 0.22 -0.07 0.01
VCAM-1 0.05 -0.10 -0.03 0.81 -0.13 -0.09 0.20 0.13
Triglycerides 0.04 0.87 0.09  -0.00 -0.02 0.03 -0.01 0.09
Total chol -0.08 0.11 0.94 -0.10 0.04 -0.01 -0.01 -0.02
HDL chol -0.20 -0.61 0.32 -0.19 -0.03 0.26 0.16 -0.02
LDL chol 0.05 -0.12 0.86 -0.05 0.05 -0.12 -0.11 -0.04
Apo B 0.16 0.74 0.55 -0.08 -0.12 -0.02 -0.06 0.04
LDL size 0.05 -0.83 0.12 -0.04 -0.01 -0.09 0.06 -0.04
 
Extraction Method: Principal Component Analysis.
Rotation Method: Varimax with Kaiser Normalization. 
Variables with loadings outwith the -0.40 to 0.40 are bolded.
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In accordance with our previous fi ndings in Study I, only the “duration factor” 
(R = 0.298, p < 0.001) and the “blood pressure factor” (R = 0.318, p < 0.001) 
correlated signifi cantly with Max IMT.  When all factors were entered as variables 
in the linear regression analysis to explain variation of Max IMT, the “duration 
factor” (T = 5.8, p < 0.001), the “blood pressure factor” (T = 5.6, p < 0.001), 
and gender (T = -4.2, p < 0.001) were the main determinants of Max IMT, 
which combined  accounted for 23.6 per cent of the variation. The “dyslipidaemia 
factor”, the “obesity factor”, and the “cholesterol factor” also remained in the 
model. These combined  explained 25.2 per cent of the variation in MaxIMT 
(Study III).
In the healthy control group we performed linear regression analysis to examine 
determinants of MaxIMT, which according to the fi nal model were age, hSAA, 
LDL cholesterol, HOMA IR and VCAM-1 (Study III). Interestingly, contrary 
to that found for the diabetic cohort, there was not even a trend of a correlation 
between Max IMT and blood pressure variables in the healthy control group 
(Study III).
6.5. Pulse wave analysis (PWA), intima-media thickness 
(IMT), and carotid plaques (Study IV and unpublished 
data) in type 2 diabetic subjects
Study IV analysed associations of aortic pressure, central pressure augmentation 
and augmentation index (AIx) with carotid IMT and plaques in type 2 diabetic 
patients. 
Determinants of MaxIMT were calculated separately for each gender. Interestingly, 
while both brachial and aortic systolic and mean blood pressures were similar 
between the genders, in females the diastolic blood pressure was lower and the 
pulse pressure was higher than in males for both the brachial artery and the 
aorta. Accordingly, both central pressure augmentation and the AIx were higher 
in females than males even after adjusting for height and smoking. In females, 
central pressure augmentation, and aortic systolic blood pressure, but not brachial 
systolic blood pressure, were age-independent determinants of MaxIMT as 
determined by multiple linear regression analysis (R2 24.9 %, p < 0.001).
In males, the central pressure augmentation, and the aortic systolic blood 
pressure, but not the brachial systolic blood pressure, explained 27.8 per cent of 
variation of MaxIMT independently of age and weight as determined by linear 
regression analysis. After adjusting for confounders, albuminuria correlated with 
augmentation and with Max IMT (Studies I and IV).
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We also entered the factors derived in Study III (Table 10) together with 
gender in a GLM multivariate model to determine the augmentation and AIx 
(Unpublished). The model  accounted for only 16 per cent of the variation in AIx, 
and the signifi cant determinants of AIx were gender (p < 0.001), blood pressure 
factor (p < 0.01) and – interestingly – the endothelial factor (p = 0.015). 
The GLM model for augmentation was more fi tting and explained 32 per cent 
of the variation in augmentation. The signifi cant determinants for augmentation 
were the blood pressure factor (p <  0.001), gender (p < 0.001), the duration 
factor (p = 0.004), the obesity factor (p = 0.008), and the endothelial factor 
(p = 0.04). It is noteworthy that the cholesterol, dyslipidaemia, glucose, and 
infl ammation factors were not associated with either augmentation of AIx.
A total of 99 carotid scans of the diabetic patients were randomly selected for 
evaluation of focal soft and mineralised changes (= plaques). In Study IV, 97 
scans were analysed. Characteristics between these 97 patients and the whole 
diabetic study cohort were similar (Study IV). Soft plaques were present in 70 
subjects (61%), and mineralised plaques in 48 patients (49%). 
The severity of soft plaques as well as the severity of mineralised plaques correlated 
signifi cantly with Max IMT for both genders (Figures 6 and 7). 
Figure 6. Mean of Max IMT according to the soft plaque score. 
0 = no change, 
1 = thickening of artery wall (IMT ≥ 1.5mm at CCA and/or ≥ 2mm 
at CB or ICA), 
2 = protrusion of 25 – 39% of the lumen diameter, 
3 = protrusion over 40% of the lumen diameter
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Figure 7. Mean of Max IMT according to the mineral plaque score. 
0 = no mineralisation
1 = solitary mineralisation
2 = several mineralisations or a cluster of mineralisations
 
Genders combined, the severity grade of the mineralised plaques correlated 
with an increase in IMT, central pressure augmentation, and increases in both 
peripheral and central systolic and pulse pressures (Study IV).  When the subset 
with the plaque scores scanned was divided according to gender, the differences 
between augmentation and the categories for mineralised plaques became non 
signifi cant. This was obviously due to the lack of power in this study (data not 
shown).
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7. Discussion 
7.1. Study subjects
Our diabetic patients represent a wide range of middle-aged and elderly type 
2 diabetic subjects with regard to diabetes duration and treatment options. 
There fore we consider our study cohort to be relatively representative of people 
commonly seen at an outpatient diabetes clinic, even though the subjects were 
recruited by newspaper advertisements and from several different outpatient 
clinics. The lipid inclusion criteria of the diabetic patients were determined to 
allow inclusion of  subjects with mild diabetic dyslipidaemia, but not patients 
requiring open-label hypolipidaemic therapy. The inclusion criteria of healthy 
controls were assumed to allow inclusion of subjects representative of healthy 
population. The mean level of cholesterol in Finland was 5.5 mmol/l in late 
1990 s´ in both genders (Vartiainen et al 2003). The mean concentrations of 
total and LDL chol were comparable in diabetic subjects and healthy controls 
and actually lower than in the general population despite different inclusion 
criteria for diabetic subjects and healthy controls. Due to inclusion criteria, none 
of the participants had hypolipidaemic treatment, which excludes any effects by 
statins on lipids and infl ammation.
The lipid values of our diabetic subjects were slightly better than those reported in 
the UKPDS (Turner et al. 1998) and DAIS (Diabetes Atherosclerosis Intervention 
Study Investigators 2001), which may give rise to an underestimation of the 
potential of lipoproteins as determinants of IMT.  The imbalance in gender 
distribution was adjusted for in the statistical analyses.
The presence of CVD was determined on clinical history. All hospital records 
available were reviewed. The electrocardiograms will be analysed separately in 
the FIELD main study for detecting silent ischaemia.
Our control group consisted of healthy individuals, with the exception that we 
allowed for the presence of mild hypertension and its treatment. We excluded 
from this cohort subjects with derangement of glucose metabolism as well as high 
total cholesterol, LDL cholesterol, and triglyceride values. Consequently, the 
number of control subjects with the metabolic syndrome was low in comparison 
with the general population, and also the anthropometric measurements were 
more favourable than those found in our diabetic patients. To fi nd control 
patients matched for age, gender, and anthropometric measurements, but free 
of glucose derangement and dyslipidaemia, would have been an impossible task. 
Therefore we strived to compensate for the different confounders in our statistical 
analyses.  Obviously, our results obtained from the healthy control group cannot 
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as such be extrapolated to the general population, as our “healthy” subjects in all 
probability are healthier than people in the general population.
7.2. The HOMA model
We used homeostatic model assessment (HOMA) for determining insulin 
resistance. The HOMA is a method for assessing β-cell function and/or insulin 
resistance (IR) from the basal concentrations of glucose and insulin using a 
simple mathematical calculation (Matthews et al. 1985). In a newer computerised 
modifi cation of the HOMA model C-peptide can also be used as an alternative 
to insulin (Levy et al. 1998). 
The HOMA model has been used in over 500 studies and has been validated against 
other measures of insulin resistance (euglycaemic clamp and minimal model) and 
β-cell function (hyperglycaemic clamp, acute insulin response in intra-venous 
glucose tolerance test, and continuous glucose infusion model assessment) (Wallace 
et al. 2004). The updated computer model accounts for variations in hepatic and 
peripheral glucose resistance (Levy et al. 1998), and is therefore recommended 
when comparing the HOMA model with other models (Wallace et al. 2004). 
The original HOMA model, which we used, systematically underestimates insulin 
sensitivity and is thus not optimal for assessing absolute resistance (Wallace et al. 
2004). When assessing relative change or comparing groups, the original model 
functions well, as the underestimation error is consistent.
HOMA IR depends upon both peripheral and hepatic insulin sensitivity. In a 
recent analysis comparing the HOMA model in NGT, IFG, IGT, IFG/IGT, and 
type 2 diabetic subjects, the HOMA IR correlated with the M-value obtained 
during the euglycaemic clamp in NGT and type 2 diabetic subjects (Tripathy et 
al. 2004). In the IFG and IFG/IGT groups the correlation between HOMA 
IR and the M value was not signifi cant. In prediabetic individuals the HOMA 
IR refl ected mainly the hepatic insulin resistance instead of the total insulin 
resistance. The implication of these results for our study is that HOMA IR 
reliably mirrors insulin resistance in type 2 diabetic and NGT subjects. 
The HOMA IR model has been reported to be more biologically variable regarding 
type 2 diabetic patients than in subjects with NGT (Jayagopal et al. 2002). On the 
other hand, a study comparing several simple indices of insulin resistance and the 
glucose disposal rate in euglycaemic hyperinsulinaemic clamping demonstrated 
that the logarithmic transformation of HOMA IR – which we used – and the 
Quantitative Insulin Sensitivity Check Index provided repeatable estimates of 
insulin sensitivity with excellent discriminating potential (Mather et al. 2001). 
As a conclusion, the logarithmic transformation of HOMA IR is to be 
recommended as a measure of insulin sensitivity in large studies when clamp 
techniques are not feasible.
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7.3. Intima-media thickness
7.3.1. The IMT method
Different  techniques to measure IMT and reproducibility of results have been 
thoroughly reviewed by Kanters et al. (1997). Overall the analogy of the far wall 
IMT with histology is more accurate than that of the near wall: sonographic 
measurement of the near wall produces an IMT fi gure that is only 80% of 
the actual histological thickness (Wong et al 1993). On the other hand this 
difference is systematic and therefore does not give biased associations (Kanters 
et al. 1997). Combining near wall and far wall measurements together seems to 
reduce variability and thus increase reliability of the results (Bots et al. 2003). 
The most easily scanned region is the common carotid artery (CCA). There 
is more variability and missed images in scanning the internal carotid artery 
(ICA) or the bifurcation/carotid bulb (CB). On the other hand, plaques appear 
earlier at the bifurcation and in ICA than in CCA. Performing ultrasound scans 
at different angles and at several sites and calculating the common mean values 
from these measurements has given results corresponding more closely with 
CVD than measurements performed at individual sites (Kanters et al. 1997). 
A pooled analysis and evaluation of prospective trials using IMT measurements 
as surrogate end points of CVD (Bots et al. 2003) recommends the mean of 
maximal IMT measurements from several sites at the carotid artery as a primary 
outcome measure, and both near and far wall sonographic measurements, to 
reduce measurement error, increase precision, and estimate the severity and extent 
of the carotid atherosclerosis in a reliable way.  Segment-specifi c measures can be 
used as secondary outcomes. Thus our decision at the beginning of the study to 
apply a complex IMT protocol with scanning at several carotid sites, both NW 
and FW, at three imaging angles, for both the left and the right carotid arteries, 
was in line with their recommendations.
7.3.2. IMT and its determinants
We demonstrated for the fi rst time that IMT is thicker in type 2 diabetic patients 
at all ages between 50 to 75 years (Study III). This is consistent with previous 
data showing that IMT is thicker in diabetic patients than healthy controls 
(Yamasaki et al. 1995, Yamamoto et al. 1997, Mykkänen et al. 1997, Temelkova-
Kurktschiev et al. 1999, Goff et al. 2000, Mohan et al. 2000, Bonora et al. 
2000). It has been reported that IMT is already elevated before the onset of 
diabetes (Hunt et al. 2003). IMT is potentially partly genetically determined 
(Lange et al. 2002), and also elevated in glucose-tolerant fi rst-degree relatives of 
type 2 diabetic patients (Pannacciulli et al. 2003). 
In accordance with the fi ndings of previous studies, age, gender, duration of 
diabetes, and blood pressure were the most important determinants of IMT in 
our type 2 diabetic patients (I, III). In Study I, Lp(a) remained in the linear 
7. DISCUSSION
225333Leinonen.indd   59 1.5.2005   10:54:21
60
regression model to explain IMT as a signifi cant but only moderate determinant. 
Similarly, in Study III, the “dyslipidaemia factor” representing diabetic 
dyslipidaemia with high triglycerides, low HDL and small LDL particle size, 
as well as the “cholesterol factor” representing high total and LDL cholesterol 
and high Apo B, remained in the model as weaker determinants of IMT than 
the “duration factor” and “blood pressure factor”.  Diabetic patients with lipid 
values requiring open lipid-lowering therapy were excluded from the FIELD 
study, therefore the importance of lipids as determinants of IMT might have 
been underestimated in our study. On the other hand, earlier research suggests 
that as a rule the association between lipids and IMT is not as strong as in 
non-diabetic cohorts (Yamasaki et al. 1995, Temelkova-Kurktschiev et al. 1999, 
Mohan et al. 2000, Goff et al. 2000, Kong et al. 2000).
Against our expectations, we did not detect any association between IMT 
and the acute phase reaction and endothelial dysfunction markers among the 
diabetic group, despite thicker IMT and higher levels of these markers in type 2 
diabetic subjects than in healthy controls (Study III). Very recently other groups 
have reported similar observations. Moussavi et al. (2004) compared carotid 
IMT and the levels of E-selectin, ICAM-1, VCAM-1, CRP, and 8-isoprostane 
(a marker of oxidative stress) in 40 type 2 diabetic patients and 25 healthy 
controls. These authors found that in a diabetic group with good glycaemic 
control and no clinical CVD, the concentrations of E-selectin, ICAM-I, CRP, and 
8-isoprostane were signifi cantly higher than in the control group. However they 
also found that the results in IMT were similar in diabetic and healthy subjects. 
Their results also show an association between CRP and waist circumference in 
agreement with our data. A Swedish group (Sigurdardottir et al. 2004) recently 
published a population-based study on 271 61-year-old men including subsets 
with established diabetes, newly diagnosed diabetes, and healthy controls. In 
that study, a composite end-point of IMT and carotid plaque size increased 
gradually from healthy controls to newly diagnosed diabetic subjects and men 
with established diabetes. CRP levels were higher in both diabetic subgroups, 
but did not explain the variation in the composite IMT. 
There was  no association between low-grade infl ammation and IMT in our study. 
Likewise, the infl ammatory and/or endothelial markers were not related to the 
presence of CVD in our diabetic patients. It has been reported previously that 
carotid IMT correlates weakly with angiographically determined coronary artery 
disease (Adams et al. 1995, Zebrack et al. 2002). In the study by Zebrack et al, 
the correlation between CRP and the severity of CAD was weak, but both factors 
predicted future CAD events independently and additively. In the ARIC study, 
baseline levels of CRP were not related to carotid IMT after adjustment for other 
major risk factors. CRP predicted CAD incidence, though this association became 
less pronounced after adjusting for confounding factors (Folsom et al. 2002).
The process of increasing IMT differs from the pathogenesis of acute cardiovascular 
events.  Infl ammation and endothelial activation are implicated in the initiation 
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of atherosclerosis, in the prothrombotic state, and in the development of 
vulnerable plaques prone to rupture (Tedgui and Mallat. 2001). As a matter 
of fact, nearly two-thirds of all coronary deaths are attributable to plaque 
rupture, and a substantial number of the rest are due to plaque erosion (Madjid 
et al. 2004). IMT, on the other hand, is closely correlated to hypertension, and 
potentially does not refl ect only atheromatosis, but also changes in the smooth 
musculature of the vascular wall (Devynck et al. 2004). The complex biological 
process ending in the development of an unstable atheroma, thinning of the 
cap, plaque rupture and presentation of a clinical CVD event conceivably may 
not be well predictable by IMT. New imaging techniques to identify activated, 
vulnerable plaques are being developed, such as intravascular ultrasound (IVUS), 
angioscopy, thermography, spectroscopic methods, etc. (Fayad and Fuster 
2001). So far no easily repeatable, safe, non-invasive and reliable methods exist 
(Schoenhagen et al. 2004).
We could for the fi rst time demonstrate a link between IMT and IGFBP-1, which 
according to our results (Study I) and previous research is an inverse marker of 
insulin resistance (Mohamed-Ali et al. 1999, Ricart and Fernández-Real 2001). 
However, other factors beside insulin resistance must also be operating, as there 
was no signifi cant association between HOMA IR (calculated for patients without 
insulin treatment) and MaxIMT in the diabetic subjects whether or not adjustments 
for the factors of age, gender, BMI and diabetes duration were used. 
Almost simultaneously with the publication of our results (I) Heald et al. 
(2002) demonstrated an association between low IGFBP-1 and the presence 
of macrovascular disease and hypertension in type 2 diabetic patients. On the 
other hand, in a general elderly male Finnish population cohort, high IGFBP-1 
levels correlated with increased cardiovascular mortality (Harrela et al. 2002). 
These cross-sectional studies were performed in different populations, which 
may partly explain the contradicting results.
Recently, prospective studies of the IGF system in regard to CVD have been 
published. When individuals without ischaemic heart disease (IHD) were 
followed for 15 years, a low level of IGF-I at baseline was associated with a 
two-fold increased  incidence of ischaemic heart disease  (Juul et al. 2002). 
In a 9-13 year follow-up of the Rancho Bernardo Study cohort, consisting of 
elderly men and women, low baseline concentrations of IGF-I and IGFBP-1 
were independently and jointly related to IHD mortality (Laughlin et al. 2004). 
In this study, the IGFBP-1 levels were lower in the subset with diabetes or IGT 
than in those with NGT, and, in accordance with our results, nearly 50 per cent 
lower among those with insulin resistance than in those without. These authors 
demonstrated that the association between IHD and the levels of IGF-I and 
IGFBP-1 existed in all categories of glucose tolerance.
Taken together, low IGFBP-1 seems to be a risk marker for subsequent CVD 
events probably due to its strong association with insulin resistance.
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7.4. The metabolic syndrome
7.4.1. The defi nition of the metabolic syndrome
For practical reasons, in the present study the diagnosis of the metabolic syndrome 
was determined by the NCEP criteria. The criterion of the OGTT value, included 
in the WHO criteria, would not have been relevant  in our diabetic patients 
nor in the healthy control group, the latter only being included if their 2-hour 
glucose tolerance test was normal. Furthermore, our study cohort was too large 
to perform clamp studies to investigate insulin resistance. The NCEP criteria 
have the additional benefi t that all criteria are readily available in clinical practice. 
Thus the obtained results can be transferred into patient treatment.  
Hanley et al. (2003) compared the WHO and NCEP criteria in detecting 
insulin resistant subjects among the non-diabetic participants of the Insulin 
Resistance Atherosclerosis study, using frequently sampled intravenous glucose 
tolerance test -derived measures as reference values for insulin sensitivity. Both 
criteria identifi ed insulin resistant individuals, but the WHO criteria were more 
sensitive. 
It has been speculated that the predictive value of the two sets of criteria (NCEP 
and WHO) for the metabolic syndrome may depend on the prevalence of the 
core metabolic components – dyslipidaemia, hypertension, obesity, and glycaemia 
– in the population investigated (Hunt et al. 2004). Thus the usefulness of the 
NCEP vs. WHO criteria with a differing emphasis on the components of the 
metabolic syndrome may vary according to the background population.
7.4.2. The IGF system and the metabolic syndrome
We demonstrated that IGFBP-1 has a strong inverse relationship with the 
number of metabolic syndrome features in type 2 diabetic patients: the more 
profound the metabolic syndrome, the lower was the IGFBP-1 concentration. 
As insulin potently suppresses IGFBP-1 production, this inverse correlation 
may partly result from an increased concentration of insulin present during 
insulin resistance. In our diabetic patients the duration of diabetes and thus 
also endogenous insulin production was highly variable. The treatment modes 
included diet, different combinations of oral treatment, and insulin treatment, 
which also modify circulating insulin levels. Therefore it was no surprise that the 
relationship between serum insulin and the degree of the metabolic syndrome 
was less consistent (Fig 4). Why IGFBP-1 seems to be a better predictor of 
metabolic syndrome than insulin cannot be explained in a research setting such 
as ours, but would require studies on the putative mechanism.
Interestingly, a recent study reported a strong inverse correlation between 
IGFBP-1 and waist circumference as well as IGFBP-1 and the presence of the 
metabolic syndrome (Kaushal et al. 2004). CRP, on the other hand, correlated 
positively with waist circumference and the presence of  metabolic syndrome. 
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When analysed together, subjects with an IGFBP-1 concentration below median 
and a CRP concentration in the highest tertile, had a 36-fold increased risk of the 
metabolic syndrome compared with subjects having an IGFBP-1 concentration 
above median and a CRP concentration in the lowest tertile. The risk was for the 
most part independent of age, gender, and fasting insulin concentration.
The complex cross-talk between the IGF system and other metabolic systems 
is so far not fully understood. The IGF system interacts with other growth 
factor systems, cytokines, lipoproteins, haemodynamic forces etc. IGFs exert 
various hormonal and auto/paracrine effects, including processes involved in the 
development of atheroma. IGFBPs and IGFBP proteases not only regulate the 
amount of free IGFs in serum, but have additionally IGF-independent functions. 
Understanding the mechanisms requires to be addressed by basic research 
(Delafontaine et al. 2004).
7.4.3. Infl ammation, endothelial activation, insulin resistance, and 
the  metabolic syndrome
We detected a strong association between endothelial activation, infl ammation, 
and the severity of the metabolic syndrome (Study II). These results are in line 
with those of Weyer et al (2002). They showed that the serum concentrations 
of CRP, sPLA2, and ICAM-1 in a cohort of 32 non-diabetic Pima Indians were 
closely correlated with the amount of body fat, BMI, waist-to-hip-ratio, and fasting 
insulin. Insulin-dependent glucose disposal investigated by the clamp technique 
was inversely related with the levels of CRP, sPLA2, ICAM-1, E-selectin, and 
von Willebrand factor (vWF).  E-selectin and vWF also correlated with CRP. 
The authors concluded that the levels of infl ammatory markers increase with 
increasing obesity, whereas endothelial activation mainly increases in proportion 
to the extent of infl ammation and insulin resistance. In prediabetic individuals, 
the degree of infl ammation has been shown to be higher in subjects who are 
insulin resistant in comparison with subjects with primarily defi cient insulin 
secretion (Festa et al. 2003). 
Our fi nding of a positive relationship between glycaemic control and low-grade 
infl ammation and endothelial activation is in line with previous research, which 
demonstrated a decrease of infl ammatory and endothelial markers by improving 
glycaemic control (Ryysy et al. 2001, King et al. 2003). Our cross-sectional 
results could not answer if increased glycaemia causes infl ammation or vice versa. 
Interestingly, Ryysy et al (2001) could demonstrate a correction of E-selectin 
levels with intensive insulin treatment of type 2 diabetic patients.
We demonstrated that all markers for low-grade infl ammation and endothelial 
activation correlated signifi cantly, most of them strongly, with waist circumference 
in our diabetic patients. In the healthy and comparatively lean study subset 
the relationship was weaker, and only CRP and E-selectin were signifi cantly 
associated with waist circumference.
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There is increasing evidence that abdominal fat is a key regulator in the 
infl ammatory process (Tracy 2001). When pre-menopausal women with the 
polycystic ovary syndrome (PCO) were compared with healthy women paired 
for BMI, obesity and smoking, there was no difference in the concentrations of 
several infl ammatory markers even though the patients with PCO were more 
insulin resistant. When both groups were analysed together, the levels of CRP 
and IL-6 increased signifi cantly with increasing weight (Escobar-Morreale et al. 
2003). Omental adipose tissue fragments obtained from obese subjects released 
IL-6 two- to three-fold more than the same patients’ subcutaneous adipose 
tissue fragments (Fried et al. 1998). This implies that one of the mechanisms 
why abdominal obesity is detrimental may be that abdominal obesity enhances 
infl ammation more than peripheral obesity.
Obesity and insulin resistance are highly intercorrelated, but a defi nitive answer 
as to the question, which is the primary defect in the metabolic syndrome, 
remains open. In a Chinese cohort including healthy, diabetic, hypertensive, and 
dyslipidaemic individuals, examined by factor analysis, obesity rather than insulin 
resistance seemed to be the seminal abnormality behind the metabolic syndrome 
(Anderson et al 2001). Moreover, in Caucasian cohorts, obesity, especially central 
adiposity, has been a central disorder behind the metabolic syndrome (Vanhala 
et al. 1998, Maison et al. 2001, Lemieux 2001). However, some studies provide 
evidence for the role of insulin resistance over obesity as the unifying factor in 
the metabolic syndrome (Meigs et al 1997). In a recent prospective analysis 
by Laaksonen et al (2004), baseline values of CRP predicted the development 
of both diabetes and the metabolic syndrome, suggesting that infl ammation 
may be the primary defect. However, while the association between CRP levels 
and the risk of diabetes remained after adjusting for lifestyle factors and other 
confounders, the relationship between CRP and the incidence of the metabolic 
syndrome was no longer signifi cant.
7.4.4. The metabolic syndrome and CVD
We could not demonstrate any association between the presence or severity of 
the metabolic syndrome with either IMT or clinical CVD in our study subjects. 
This fi nding contradicts with those of a large number of reports in the literature 
confi rming the importance of the metabolic syndrome as a cardiovascular 
risk factor (reviewed by Isomaa 2003). Our study was not a population-based 
epidemiological study. Instead we investigated diabetic subjects, over three 
quarters of whom had the metabolic syndrome both in the subset with CVD as 
well as in the subset without clinical CVD. Thus the power of the study probably 
would not have been suffi cient for showing a difference in the prevalence of 
the metabolic syndrome between subsets divided according to the presence of 
clinical CVD even if such a difference existed. The cross-sectional nature of our 
study may also partly explain the apparent lack of association between CVD and 
the metabolic syndrome.
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In the San Antonio Heart Study,  NCEP and WHO criteria were compared 
in regard to their predictive value in the general population for cardiovascular 
and all-cause mortality (Hunt et al. 2004). Interestingly, the presence of the 
metabolic syndrome was a stronger risk factor for CVD and all-cause mortality in 
women than in men.  In that study, the predictive value of the NCEP defi nition 
was greater than the WHO defi nition. 
The value of the NCEP defi nition is also highlighted in a cross-sectional analysis 
of the NHANES study (Alexander et al. 2003). In that cohort, patients with both 
diabetes and the metabolic syndrome had the highest prevalence of CHD, whereas 
the prevalence of CHD was low in subjects without the metabolic syndrome 
regardless of their diabetes status. A subgroup with the metabolic syndrome as 
defi ned by NCEP criteria was identifi ed among the prospective Bruneck study 
(Bonora et al. 2003). Subjects with metabolic syndrome at baseline had a higher 
incidence and progression of carotid plaques, stenosis, and CVD than individuals 
without the metabolic syndrome. In the study by Lakka et al. (2002), the presence 
of the metabolic syndrome according to the WHO defi nition was associated with 
CHD, CVD, and all-cause mortality, whereas the metabolic syndrome as defi ned 
by the NCEP criteria only correlated with CHD mortality. The Botnia Study 
used the 1998 WHO criteria (Isomaa et al. 2001). In that cohort the metabolic 
syndrome carried a markedly increased risk for CV mortality.
Recently, the Women’s Ischemia Syndrome Evaluation (WISE) Study investigated 
and followed 780 women referred for coronary angiography due to suspected 
ischaemia, for the presence or absence of the metabolic syndrome, diabetes, and 
prevalence of CAD as well as 3-year risk for CVD (Kip et al. 2004, Marroquin et 
al. 2004). The metabolic syndrome and BMI were strongly associated with each 
other, but only the metabolic syndrome correlated with CAD. Furthermore, 
BMI did not determine 3-year risk of death or major CVD events. However, each 
unit of BMI increased with the degree of metabolic progression from normal 
through metabolic syndrome to diabetes and was associated with approximately 
a two-fold higher risk of death and major CV events (Kip et al. 2004). 
In the WISE study, the levels of IL-6 and CRP were higher in women with 
either diabetes or metabolic syndrome than in women with a normal metabolic 
state. However, the levels of CRP did not affect the subsequent mortality or 
CVD incidence in women without angiographic CAD, and in women with 
angiographic CAD the effect of CRP was marginal (Marroquin et al. 2004). 
Thus these results support our fi ndings in demonstrating that even though 
enhanced infl ammation is part of the metabolic syndrome, infl ammation may 
not be a major determinant of CVD independently of it.
In a cross-sectional study of a type 2 diabetic cohort, CRP and fi brinogen were 
intercorrelated; CRP was related to the presence of the metabolic syndrome 
features but not to macrovascular disease prevalence. However, fi brinogen was 
higher in patients who had undergone a CV event or revascularisation or had 
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microalbuminuria (Streja et al. 2003). Therefore CRP may not be as good a 
predictor of macrovascular disease in type 2 diabetic patients as in the general 
population. On the other hand, in the same study fi brinogen was found to be a 
determinant of CVD independent of CRP. 
Very recently, infl ammation (Amar et al. 2004, Okamura et al. 2004, Kampus et 
al. 2004, Pirro et al. 2004) and body fat (Ferreira et al. 2004) have been linked 
with arterial stiffness. Thus arterial stiffness is potentially one of the mechanisms 
linking low-grade infl ammation with cardiovascular disease.
7.5.  Pulse wave analysis (PWA) 
7.5.1. The PWA method
We chose the practical and reproducible method of pulse wave analysis to 
estimate central aortic pressure, augmentation and augmentation index. The 
transfer function used to calculate the corresponding ascending aortic pressure 
waveform from the radial artery waveform measured by applanation tonometry 
has been previously validated (Karamanoglu et al. 1993, Pauca et al. 2001). 
The concept of using a generalised transfer function validated in a non-diabetic 
population for assessing diabetic patients has recently been challenged (Hope 
et al. 2004, Mather et al. 2004). The process of arterial stiffening occurs early 
in the development of diabetes (Salomaa et al. 1995), and the physical changes 
induced by diabetes in the vessel wall, including collagen cross-linking and other 
consequences of advanced glycosylation end product binding, may change the 
relationship of the waveforms centrally and peripherally (Mather et al. 2004). 
The Hoorn study investigators have examined the estimates of arterial stiffness 
with the glucose tolerance status (Schram et al. 2004). They measured total 
systemic arterial compliance 1) by the same commercial PWA method, which we 
used in the present study, and 2) by calculating the ratio of the stroke volume to 
aortic pulse pressure. Aortic pulse pressure was estimated by two methods: one, 
which applies a calibration method using distension waveforms at the brachial 
and carotid arteries to calibrate the pulse pressure at the carotid artery, and 
the other by applanation tonometry. These authors calculated the AIx (Schram 
et al. 2004). Furthermore, they measured the carotid-femoral transit time by 
continuous measurement of the diameter of the carotid and femoral arteries. The 
calculated total systemic arterial compliance results were comparable by the two 
methods. It was found that compliance deteriorated gradually by a worsening 
of glucose tolerance from NGT to IGF/IFG and type 2 diabetes. AIx increased 
and carotid-femoral transit time decreased with declining glucose tolerance. 
Measures of glycaemia (HbA1c, fasting and postload glucose) accounted for up 
to 50 per cent of the decrease in arterial compliance. 
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A greater error in the generalised transfer function derived central systolic pressure 
compared with invasive central systolic pressure results has been reported in type 
2 diabetic patients than in individuals with NGT (Hope et al. 2004). This should 
not hinder the use of PWA for detecting relationships between augmentation and 
AIx and metabolic parameters or measures of vascular disease among diabetic 
patients. As the potential error is systematic for all diabetic subjects, we consider 
our results demonstrating an association between the measures of central systolic 
pressure and carotid IMT and mineralised plaques reliable.  
7.5.2.  PWA, IMT, and plaque score
We detected a close relationship between IMT and measures of central arterial 
pressure such as augmentation and augmentation index in study IV. This is in line 
with our previous fi ndings that pulse pressure and, through factor analysis, the 
blood pressure factor, were important determinants of IMT (Studies I and III). 
Interestingly, when we analysed the factors as determinants of augmentation and 
AIx, we found that the endothelial factor, in addition to the blood pressure and 
duration factors, was also a determinant of augmentation and AIx. Obviously 
arterial stiffening includes endothelial damage.
In study IV, pulse pressure and central pressure augmentation were higher in 
female than male diabetic subjects, even after controlling for smoking and height, 
which may affect the wave refl ections and thus central augmentation. This may 
indicate that diabetes has a more detrimental effect on large artery stiffness and 
central haemodynamics in women than men. This refl ects the fact that diabetic 
women are especially predisposed to cardiovascular morbidity (Barrett-Connor 
et al 1991). 
An increasing number of mineralised focal changes was related to age, MaxIMT, 
and variables refl ecting arterial stiffness. These include aortic pulse pressure, 
brachial pulse pressure, aortic and brachial systolic pressure, and central pressure 
augmentation. Our results showed  a correlation between IMT and large arterial 
stiffness and are consistent with the study by Fukui et al (2003) who demonstrated 
that plaque score was associated with augmentation in a Japanese type 2 diabetic 
cohort. Our results could imply that if used in clinical practice, PWA might 
reveal the presence of incipient atherosclerosis better than traditional markers 
such as lipoproteins. Nevertheless, it may be premature to recommend PWA as 
a substitute for conventional blood pressure measurements in clinical practice 
while all treatment guidelines so far are as yet based on conventionally measured 
blood pressure values.
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8. Summary of Results and Conclusions
The results of studies I – IV and the presented unpublished data can be 
summarised as follows:
1. IGFBP-1 was inversely associated with IMT in type 2 diabetic patients. 
IGFBP-1 was furthermore a marker of insulin sensitivity and inversely related 
to the severity of the metabolic syndrome among diabetic subjects.
2. Low-grade infl ammation and endothelial dysfunction were enhanced in 
type 2 diabetes. The severity of the metabolic syndrome correlated linearly 
with the levels of markers for infl ammation and endothelial activation. The 
concentrations of these markers were similar in diabetic patients with or 
without CVD.
3. Carotid IMT was thicker in type 2 diabetic patients than in healthy subjects 
over the entire age range in this study. Among diabetic subjects, patients with 
CVD had greater IMT, but the difference was not independent of recognized 
CVD risk factors. The main determinants of IMT in diabetic patients were 
blood pressure, age, gender, and the duration of diabetes. Dyslipidaemia 
and obesity were weaker determinants of IMT. In healthy subjects, the 
determinants of IMT were age, infl ammation (hSAA), endothelial activation 
(VCAM-1), LDL cholesterol, and insulin resistance (HOMA IR). Blood 
pressure was not correlated with IMT in healthy subjects, although it was 
one of the main determinants of IMT in diabetic patients. Endothelial and 
infl ammatory variables, on the other hand, were only correlated with IMT in 
the healthy subset.
4. Central pressure augmentation, the AIx (measure of arterial stiffness), and 
IMT were correlated with each other and with the severity of local vessel 
wall thickenings (soft and mineralised plaques). Diabetic women had higher 
augmentation and AIx values than men after controlling for confounders. 
After adjusting for gender, age, and heart rate, the only determinants of 
the AIx were blood pressure, albuminuria, and IMT. In factor analysis, 
also obesity and endothelial dysfunction were weak determinants of AIx in 
diabetic patients.
Low-grade infl ammation has been recognized to predict both CVD and type 2 
diabetes in population samples. Some investigators already recommend measuring 
of ultrasensitive CRP as a CVD risk marker. According to our results and some 
other recent data, CRP levels cannot among diabetic patients discriminate 
subjects with clinical or subclinical CVD from patients without CVD. The use 
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of CRP can therefore not be recommended as a CVD risk marker among diabetic 
patients. Infl ammation seems to be an early feature of the metabolic syndrome 
occurring before the clinical presentation of diabetes and CVD. 
Diabetic women had higher central pressure augmentation and AIx than men. 
These measures of arterial stiffness correlated strongly with IMT and the severity 
of the atherosclerotic local thickenings among diabetic patients. Thus diabetes 
may have a more detrimental effect on arterial compliance in women than men. 
This fi ts well with the fi nding in several studies that diabetes seems to increase 
the risk of CVD even more in women than in men.
According to our results, the concentration of IGFBP-1 and the measures of 
central systolic pressure determined by PWA refl ect intima-media thickness and 
potentially incipient atherosclerosis among type 2 diabetic subjects, contrary 
to markers of infl ammation such as CRP. The ongoing prospective part of the 
FIELD study may, at best, elucidate which variables most accurately predict the 
incidence of cardiovascular events in this high-risk population.
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